Plein Center for Aging Faculty Archives

Clayton English

Education:

Bachelor of Science in Pharmacy Studies, University of Connecticut
Doctor of Pharmacy, University of Connecticut
MS in Health Services – Clinical and Translational Research, University of Washington

Research and Clinical Interests:

Psychiatric Pharmacy
Clinical Psychopharmacology
Drug-Induced Disease
Deprescribing
Mood Disorders
Adult ADHD
Psychostimulant Use
Interprofessional Education

Biography

Dr. Clayton English is an Assistant Professor of Pharmacy at the University of Washington School of Pharmacy. Clayton earned his Bachelor of Science and Doctor of Pharmacy degrees from the University of Connecticut in Storrs, Connecticut and subsequently completed a specialty residency in psychiatric pharmacy practice and clinical psychopharmacology at Nova Southeastern University College of Pharmacy in Fort Lauderdale, Florida. He holds board certifications in Psychiatric Pharmacy (BCPP), Pharmacotherapy (BCPS), and Geriatric Pharmacy (BCGP). From 2010 to 2022, Clayton served as a faculty member at Albany College of Pharmacy and Health Sciences (ACPHS) and practiced as a clinical pharmacy specialist in psychiatry at the University of Vermont Medical Center (UVMMC) in Burlington, Vermont. During his time in Vermont, Clayton helped expand clinical pharmacy services within inpatient psychiatry at UVMMC and precepted and assisted in the training of numerous students and residents in both pharmacy and psychiatry. Additionally, Clayton was highly involved in the didactic instruction of neuropsychiatric therapeutics and psychopharmacology across the pharmacy school curriculum.

Clayton has broad clinical and research interests in neurologic and psychiatric pharmacy including safe and appropriate use of psychiatric medications, psychotropic deprescribing, pharmacovigilance, mood disorders, adult ADHD, and drug-induced behavioral disorders. Additionally, Clayton is passionate about interprofessional education, team-based care, and student and resident well-being.

Clayton remains highly engaged in the professional development of pharmacists and enjoys participating in activities and organizations that advocate for the profession. Clayton is an active member of the American Association of Psychiatric Pharmacists (AAPP) and serves as a Senior Editor for the AAPP Psychiatric Pharmacotherapy Review Book and Course. He has been honored for his contributions to the profession and education of students and residents. He was the recipient of the Award of Excellence in Academic Teaching from the University of Vermont Psychiatry Residency Program in 2012, 2017, and 2019 and was recognized in 2013 as the Vermont Pharmacist of the Year by the Vermont Society of Health-Systems Pharmacists. Additionally, he was recognized as the ACPHS Preceptor of the Year in 2015 and Teacher of the Year of the ACPHS Vermont Campus in 2017 and 2021. Outside the classroom, Clayton enjoys exercising, road trips, spending time with his family, and exploring the greater Seattle area for the best coffee around.

Selected Publications

English C, Bode L. Major Depressive Disorder. In: Pharmacotherapy Self-Assessment Program, 2022 Book 3. Behavioral Health. Lenexa, KS: American College of Clinical Pharmacy, 2022.

English C. Depression. In: 2020-2021 Psychiatric Pharmacotherapy Review Course. College of Psychiatric & Neurologic Pharmacists. Lincoln: CPNP; 2020.

English C, Goodwin H, Dickinson JA, Rey JA. Brexanolone: A novel treatment option for postpartum depression. P&T. 2019;44(11):732-736.

Runyan S, Gething M, English C, Rabinowitz T. Pharmacotherapeutics. In: Fundamentals of Consultation Liaison Psychiatry: Neuropsychiatry. 1^st ed. Nova Science Pub Inc; 2019.

DiSciullo AA, English CD, Horn WT. Modafinil Induced Psychosis in a Patient with Bipolar 1 Depression. Case Reports in Psychiatry. 2018;2018:3.

English CD. New therapeutic options for the management of ADHD. US Pharm. 2018;43(5):1-10.

Boyd JT, English C, Lounsbury KM. Antiparkinson Drugs. In: Dowd FJ, Johnson BS, Mariotti AJ. Pharmacology and Therapeutics for Dentistry. 7^th ed. St. Louis: Elsevier; 2017.

English C, Aloi JJ. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
Clin Ther. 2015;37(4):691-715.

Harrington CA, English C, Schaefer S. Systematic review of the post-marketing surveillance of paliperidone. Journal of Symptoms and Signs. 2014;3(1):39-49.

English C, Rey JA, Schlesselman LS. Prevalence of hazardous alcohol use among pharmacy students at nine U.S. schools of pharmacy. Pharmacy Practice (Internet) 2011 Jul-Sep;9(3):162-168.

Harrington CA, English C. Adverse drug events related to ziprasidone: a meta-analysis of randomized, placebo-controlled trials. Pharmacotherapy 2011;31(9):840-849.

Jing Li

Education

PhD, Health Policy (Economics Track), University of California at Berkeley, 2016
MS, Economics, University of California at Berkeley, 2015
MA, International Comparative Education, Stanford University, 2009
BA, Economics and English, Peking University, China, 2008

Courses Taught

HEOR 597: Graduate Seminar
HEOR 598: HEOR Methodologies Seminar

Research Interests

Decision-making in Aging
Physician Behavior
Policy Evaluation
Experimental and Quasi-experimental Methods

Biography

Dr. Jing Li is a health economist with research interests in the economic, social and behavioral factors affecting individual decision-making in health and healthcare, for both providers and patients, and the impact of policies that leverage these factors to improve patient outcomes and healthcare market efficiency. Methodologically, she is interested in innovatively applying advanced experimental and econometric methods to addressing understudied questions in health economics and policy. Dr. Li’s current projects study experimentally measured social preferences (altruism) of physicians and their relationship with patient outcomes, healthcare and financial decision-making for older adults with cognitive impairments including Alzheimer’s disease and related dementias, and conflicts of interest in physician drug prescribing.

Selected Publications

https://www.ncbi.nlm.nih.gov/myncbi/jing.li.13/bibliography/public/

Abby Winter

Education

Doctor of Pharmacy (PharmD), Drake University
Master of Public Administration (MPA), Drake University
PGY-1 Community Pharmacy Residency (Ambulatory Care Focus), Creighton University
Certified Diabetes Care and Education Specialist (CDCES)

Research Interests

Diabetes
Geriatrics (Deprescribing, Ageism)
Pharmacy Education, Scholarship of Teaching and Learning
Interprofessional Education (IPE)

Courses Taught

PY3 Pharmacist Provider Series (PHRMCY 547, PHRMPR 517)
Diabetes Care (PHARM 588)
Pharmacotherapeutics for Older Adults (PHARM 549)
Pharmacotherapeutics III and VI (PHRMCY 533, PHRMCY 536)

Biography

Dr. Abby Winter is an Associate Teaching Professor of Pharmacy and is the Assistant Director for Outreach in the Plein Center for Aging. She leads the clinical and outreach efforts of the Plein Center at Era Living, a group of Seattle-area assisted living communities. She teaches in various geriatrics and diabetes courses with the Schools of Pharmacy and Nursing at UW.

Dr. Winter earned her Doctor of Pharmacy and Master of Public Administration degrees at Drake University in Des Moines, Iowa, and completed a PGY-1 Community Pharmacy Residency with a focus in Ambulatory Care and Academia at Creighton University in Omaha, Nebraska.

She is a Certified Diabetes Care and Education Specialist (CDCES, formerly CDE). Prior to working at the UW School of Pharmacy, she practiced as a Clinical Pharmacist at the University of Washington Medicine Diabetes Institute and Lipid Clinic, and prior to that was a Clinical Assistant Professor in Ambulatory Care at the University of Kansas School of Pharmacy (KU) and served as a Residency Program Director (RPD) for a PGY-1 Community Pharmacy Residency Program.

Dr. Winter’s research interests include medication management in older adults, ageism, deprescribing, diabetes, interprofessional education (IPE), and the scholarship of teaching and learning.

Dr. Winter serves on the School’s APPE Advisory Group as the Ambulatory Care Representative, the Chair of the School’s Curriculum Committee, and is a member of the IPE Planning Committee. She is also a Director in the American Society of Consultant Pharmacists (ASCP) Washington Chapter.

Douglas Barthold

Education:

PhD, Economics, McGill University

Research Interests:

Health policy and healthy aging
Chronic disease management
Alzheimer’s disease and dementia prevention and management
Disparities in utilization and effectiveness of pharmaceutical therapies
Pharmacist regulations
Health insurance design

Courses Taught:

Health Economics

Biography:

Douglas Barthold is a health economist and Associate Professor at the University of Washington, specializing in the intersection of health policies, healthcare utilization, and health outcomes, with particular focus on aging, dementia, and prescription drug policy. He is faculty at the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, serves as Co-Director of the Program in Health Economics and Outcomes Research Methodology (PHEnOM), and is a Board Member of the Washington State Prescription Drug Affordability Board. His research explores how health insurance design and prescription drug costs impact management of chronic diseases, including mid-life risk factors for dementia. Barthold holds a Ph.D. in Economics from McGill University and previously did postdoctoral research at the Schaeffer Center for Health Policy and Economics at the University of Southern California.

Selected Publications:

https://sites.google.com/site/douglasbarthold/peer-reviewed-publications

Joanne Wang

Accepting Students to Lab: Yes

Education

PhD in Pharmaceutical Chemistry, University of California, San Francisco (UCSF)
MS in Biochemistry, University of Illinois at Chicago
BS in Biochemistry, Peking University

Courses Taught

PCEUT503
PCEUT531
PCEUT201
MEDCH501

Research Interests

Transporters (PMAT, OCTs, MATEs, OATs, OATPs, P-gp, Bcrp)
Drug transport and disposition mechanisms
Transporter-mediated drug targeting, tissue toxicity, and drug-drug interactions

Biography

Dr. Wang is Professor of Pharmaceutics at the School of Pharmacy, University of Washington, Seattle. She obtained her PhD in Pharmaceutical Chemistry from the University of California at San Francisco (1998) and completed her postdoctoral training in the Depts. of Biopharmaceutical Sciences and Biochemistry at UCSF (1998-2000).

Dr. Wang’s research is focused on solute carrier (SLC) and ATP-binding cassette (ABC) transporters that shuttle drugs, nutrients, neurotransmitters, and hormones across cell membranes. Her research interests include elucidating the mechanisms and clinical impact of transporters in nutrient and drug disposition and their potential as drug targets. Ongoing projects include:

Identification and functional characterization of transporters in human placenta

Transporters at the placental barrier act as gatekeepers, regulating the influx and efflux of nutrients, drugs, and metabolites to and from the developing fetus. Despite significant progress, the expression, function, and regulation of most transporters in the human placenta remain poorly understood. This project, conducted under the University of Washington Transporter Elucidation Center (UWTEC), seeks to advance our knowledge of the mechanisms underlying the uptake and disposition of drugs, nutrients, and dietary substances during early human development. Funded by a UC2 grant from NICHD, the study aims to identify and functionally characterize solute carrier (SLC) and ATP-binding cassette (ABC) transporters in the human placenta using a multidisciplinary approach, providing critical insights into nutrient uptake and xenobiotic exposure during fetal development.

Mechanisms and PBPK modeling of drug secretion into breastmilk

Transporters in the lactating mammary gland play a critical role in pharmacology and toxicology by mediating the active transfer of drugs and nutrients into breastmilk. Medications taken by lactating individuals can be transported into breastmilk in significant amounts, potentially leading to unintended infant drug exposure and adverse effects. Currently, no methodologies exist to accurately predict drug secretion into breastmilk via carrier-mediated transport mechanisms. This project aims to address this gap by employing a systems pharmacology approach, integrating in vitro models, in vitro-in vivo extrapolation (IVIVE), and Physiologically Based Pharmacokinetic (PBPK) modeling to predict transporter-mediated drug secretion by human mammary epithelial cells.

Transporters in the disposition and tissue targeting of meta-iodobenzylguanidine

Radioiodine-labeled meta-iodobenzylguanidine (mIBG) has broad clinical applications, serving as both a diagnostic agent and a targeted radiotherapy for neuroendocrine cancers and cardiovascular diseases. Our previous research revealed that, in addition to the norepinephrine transporter (NET), mIBG is a high-affinity substrate for several polyspecific organic cation transporters, including the plasma membrane monoamine transporter (PMAT), organic cation transporters (OCT1-3), and multidrug and toxin extrusion transporters (MATEs). These transporters are likely critical in determining mIBG’s disposition and therapeutic response. This project seeks to elucidate the specific roles of these transporters in mIBG uptake across normal and tumor tissues, aiming to develop mechanism-based strategies to optimize mIBG’s therapeutic efficacy while reducing toxicity.

Selected Publications

PubMed

Rheem Totah

Accepting Students to Lab: Yes

Education

B.S. (Honors), 1995, Birzeit University, Palestine
Masters (Honors), 2000, University of Kansas
Ph.D. (Honors), 2002, University of Kansas

Research Interests

Prescription drug negative side effects in the heart, skeletal muscle and bone; associated chemical mechanisms for this toxicity
Drug-endogenous substrate interactions
Pharmacogenetics

Biography

Dr. Totah obtained her bachelor’s degree in chemistry from Birzeit University in Palestine and her master’s and PhD in medicinal chemistry from the University of Kansas. Dr. Totah is currently a professor in the Department of Medicinal Chemistry. Her research is in the area of prescription drug negative side effects especially in the heart, skeletal muscle and bone. She focuses on researching the chemical mechanisms for this toxicity. Her research is important in guiding research towards medicines with fewer side effects and safer use. Research in the Totah lab is broadly centered on drug-endogenous substrate interactions.

Recent Publications

A Rapid and Reliable Absorbance Assay to Identify Drug-Drug Interactions with Thiopurine Drugs. Russell DA, Stafford C, Totah RA. Metabolites. 2024 Dec 19;14(12):715. doi: 10.3390/metabo14120715. PMID: 39728496

Liver CYP4A autophagic-lysosomal degradation (ALD): A major role for the autophagic receptor SQSTM1/p62 through an uncommon target interaction site. He L, Kwon D, Trnka MJ, Liu Y, Yang J, Li K, Totah RA, Johnson EF, Burlingame AL, Correia MA. bioRxiv [Preprint]. 2024 Oct 14:2024.10.14.618315. doi: 10.1101/2024.10.14.618315. PMID: 39464120 Preprint.

A Rapid and Reliable Absorbance Assay to Identify Drug-Drug Interactions with Thiopurine Drugs. Russell DA, Stafford C, Totah RA. Metabolites. 2024 Dec 19;14(12):715.

Editorial: Cytochromes P450, their modulators and metabolites in cardiovascular function and disease. Adebesin AM, Roman RJ, Campbell WB, Seubert JM, Totah RA. Front Pharmacol. 2024 Dec 3;15:1531166.

A Case to Support the Continued Use of Rifampin in Clinical Drug-Drug Interaction Studies. Bercu JP, Ponting DJ, Ripp SL, Dobo KL, Totah RA, Bolleddula J. Clin Pharmacol Ther. 2024 Jul;116(1):34-37.

Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review. Wiley AM, Yang J, Madhani R, Nath A, Totah RA. Drug Metab Rev. 2024 Mar 20:1-19.

The methyltransferases METTL7A and METTL7B confer resistance to thiol-based histone deacetylase inhibitors. Robey RW, Fitzsimmons CM, Guiblet WM, Frye WJE, González Dalmasy JM, Wang L, Russell DA, Huff LM, Perciaccante AJ, Ali-Rahmani F, Lipsey CC, Wade HM, Mitchell AV, Maligireddy SS, Terrero D, Butcher D, Edmondson EF, Jenkins LM, Nikitina T, Zhurkin VB, Tiwari AK, Piscopio AD, Totah RA, Bates SE, Arda HE, Gottesman MM, Batista PJ. Mol Cancer Ther. 2023 Dec 28.

Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ω-3 and ω-6 PUFAs. Cho C, Aliwarga T, Wiley AM, Totah RA. Adv Pharmacol. 2023;97:201-227.

METTL7A (TMT1A) and METTL7B (TMT1B) are responsible for alkyl S-thiol methyl transferase activity in liver. Russell DA, Chau MK, Shi Y, Levasseur IN, Maldonato BJ, Totah RA. Drug Metab Dispos. 2023 May 3:DMD-AR-2023-001268.

Effects of Pregnancy on Plasma Sphingolipids Using a Metabolomic and Quantitative Analysis Approach. Enthoven LF, Shi Y, Fay E, Kim A, Moreni S, Mao J, Isoherranen N, Totah RA, Hebert MF. Metabolites. 2023 Sep 21;13(9):1026.

CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive Metabolizers. Czuba LC, Malhotra K, Enthoven L, Fay EE, Moreni SL, Mao J, Shi Y, Huang W, Totah RA, Isoherranen N, Hebert MF. Drug Metab Dispos. 2023 Nov;51(11):1474-1482.

Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ω-3 and ω-6 PUFAs. Cho C, Aliwarga T, Wiley AM, Totah RA. Adv Pharmacol. 2023;97:201-227.

METTL7A (TMT1A) and METTL7B (TMT1B) Are Responsible for Alkyl S-Thiol Methyl Transferase Activity in Liver. Russell DA, Chau MK, Shi Y, Levasseur IN, Maldonato BJ, Totah RA. Drug Metab Dispos. 2023 Aug;51(8):1024-1034.

Plasma hydrogen sulfide, nitric oxide, and thiocyanate levels are lower during pregnancy compared to postpartum in a cohort of women from the Pacific northwest of the United States. Zeigler MB, Fay EE, Moreni SL, Mao J, Totah RA, Hebert MF. Life Sci. 2023 Jun 1;322:121625.

The Effects of Pregnancy on Amino Acid Levels and Nitrogen Disposition. Enthoven LF, Shi Y, Fay EE, Moreni S, Mao J, Honeyman EM, Smith CK, Whittington D, Brockerhoff SE, Isoherranen N, Totah RA, Hebert MF. Metabolites. 2023 Feb 7;13(2):242.

Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation. Aliwarga T, Dinh JC, Heyward S, Prasad B, Gharib SA, Lemaitre RN, Sotoodehnia N, Totah RA. Int J Mol Sci. 2022 Oct 17;23(20):12433.

Selective deuteration of bupropion slows epimerization and reduces metabolism. Shi Y, Dinh J, Pelletier R, Raccor B, Yusuff N, Morgan AJ, Harbeson S, Uttamsingh V, Totah RA. Bioorg Med Chem Lett. 2022 Nov 15;76:129009.

Plasma epoxyeicosatrienoic acids and diabetes-related cardiovascular disease: The cardiovascular health study. Lemaitre RN, Jensen PN, Zeigler M, Fretts AM, Umans JG, Howard BV, Sitlani CM, McKnight B, Gharib SA, King IB, Siscovick DS, Psaty BM, Sotoodehnia N, Totah RA. EBioMedicine. 2022 Sep;83:104189.

Reductions in Hydrogen Sulfide and Changes in Mitochondrial Quality Control Proteins Are Evident in the Early Phases of the Corneally Kindled Mouse Model of Epilepsy. Cho C, Zeigler M, Mizuno S, Morrison RS, Totah RA, Barker-Haliski M. Int J Mol Sci. 2022 Jan 27;23(3):1434.

Future of Biotransformation Science in the Pharmaceutical Industry. Kramlinger VM, Dalvie D, Heck CJS, Kalgutkar AS, O’Neill J, Su D, Teitelbaum AM, Totah RA. Drug Metab Dispos. 2022 Mar;50(3):258-267.

Full PubMed Listing

Peggy Soule Odegard

Education

PharmD, University of Washington
Bachelor of Science in Pharmacy, UW

Research Interests

Practice advancement and diabetes

Courses Taught

Phrmcy 501: Foundations of Being a Pharmacist I
Phrmcy 502: Foundations of Being a Pharmacy II
Phrmcy 503: Advanced Pharmacy Leadership
Pharmacy 588: Diabetes Care
Pharmacy 557: Introduction to Therapeutics

Biography

Peggy Odegard, BS Pharm, PharmD, CDES, having served as the Interim Dean for the School of Pharmacy in 2022-2023, and an active pharmacist practitioner. She earned her Doctor of Pharmacy and Bachelor of Science in Pharmacy degrees from the University of Washington.

Dr. Odegard oversees the UW School of Pharmacy Doctor of Pharmacy program and is advanced diabetes care pharmacist clinician. She provides regular outreach and community-based education to older adults and to those affected by diabetes, mentoring students alongside her in this role. Her research and teaching are focused on diabetes care, pharmacy practice advancement, interprofessional education, and leadership. Dr. Odegard has published more than 60 refereed manuscripts and book chapters, and regularly presents her work nationally.

Dr. Odegard is past Chair of the UW School of Pharmacy, Department of Pharmacy and prior to her work at the UW, served as the Clinical Pharmacy Manager for a regional health system, where she gained substantial experience and training in organizational leadership, change management, and with quality improvement and implementation of pharmacy practice services.

Selected Publications

https://www.ncbi.nlm.nih.gov/pubmed/?term=odegard+ps

Leigh Ann Mike

Education

PharmD, University of Illinois at Chicago
Board Certified Pharmacotherapy Specialist (BCPS)
Board Certified Geriatric Pharmacist (BCGP)

Research Interests

Geriatrics
Deprescribing
Age-Friendly Care
Pharmacy Education, Scholarship of Teaching & Learning

Courses Taught

PHRMCY 541-543, PHRMPR 531 Pharmacist Provider Series
PHARM 548 Current Topics in Geriatrics
PHARM 550 Seminar in Geriatrics

Biography

Dr. Leigh Ann Mike is a Clinical Associate Professor of Pharmacy and Shirley & Herb Bridge Endowed Professor for Women in Pharmacy at the University of Washington. She is the Interim Director and Assistant Director for Education, both at the Plein Center for Aging. She completed her PharmD and PGY1 residency training at the University of Illinois at Chicago.

She is Board Certified as a Pharmacotherapy Specialist (BCPS) and as a Geriatric Pharmacist (BCGP). Her practice experiences have included Drug Information Specialist at Grady Health System in Atlanta, Georgia; Critical Care Pharmacist at Harborview Medical Center in Seattle, Washington; and Consultant Pharmacist at a Seattle-area assisted living community.

Her interests include the care of older adults in acute and critical care settings; humanizing/whole-person care; preparing a diverse pharmacy workforce to meet the healthcare needs of an increasingly diverse population of older adults; and developing Age Friendly Health Systems.

Selected Publications

English C, Bergeron K, Mike LA. Xanomeline/trospium combination for schizophrenia: treatment considerations for older adults. J Gerontol Nursing. 2025:51(6)7-12.
Mike LA, Hart LA. Pharmacotherapy. Self-assessment questions. In: Colburn JL, Westcott AM, Potter JF, eds. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. 12^th American Geriatrics Society; 2025.
Mike LA, Marcum ZA, Gray SL. Assessing Health and Delivering Health Care to Older Adults. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: a Pathophysiologic Approach, 12th ed. New York, NY:McGraw-Hill; 2023.
Shiferaw MW, Zheng T, Mike LA, Chan LN.Assessing the accuracy and quality of artificial intelligence (AI) chatbot-generated responses in making patient-specific drug-therapy and healthcare-related decisions. BMC Med Inform Decis Mak 24, 404 (2024).
Do J, Choi SC, Chang, Mike LA. Creating a Win-Win: A Novel Layered Learning Approach for Assessing First-Year Pharmacy Students’ Communication Skills. Curr Pharm Teach Learn 2024 May 27;16(8):102111.
Mike LA, Toy JM, Chan L-N. Nutritional Supplements in Older Adults. In: Dong BJ, Elliott DE, eds. Ambulatory Care Self-Assessment Program, 2017 Book 3. Nutritional/Gastroenterologic Care. Lenexa, KS: American College of Clinical Pharmacy, 2017

Shelly Gray

Education

PharmD, University of Michigan
MS in Epidemiology, University of Washington

Courses Taught

PHARM 562: Pharmacotherapeutics V
PHARM 550: Seminar in Geriatrics

Research Interests

Medication safety in older adults
Deprescribing
Medication use and risk for falls, fractures, dementia

Biography

Dr. Gray has been a faculty member in the UW Department of Pharmacy since 1992. She is an investigator on numerous federally funded research grants and is author of more than sixty peer-reviewed publications. Earlier in her career, she received an American Association of Colleges of Pharmacy New Investigator Award and a Career Development Award from the National Institute on Aging. She serves on the editorial board for the “Annals of Pharmacotherapy”, “Journal of the American Geriatrics Society” and “Research in Gerontological Nursing”.

Gray has served as a consultant pharmacist for Providence Elderplace. Previously, she completed a two-year fellowship in geriatrics at the University of North Carolina at Chapel Hill and a clinical pharmacy residency at Thomas Jefferson University Hospital in Philadelphia. She has served on various committees of pharmacy and geriatric professional organizations.

Selected Publications

Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015:2175(3):401-7.
Gray SL, Dublin S, Yu O, Walker R, Anderson M, Crane P, Larson E. Benzodiazepine use and risk of incident dementia or cognitive decline. BMJ. 2016;352:i90.
Gray SL, Walker RL, Dublin S, Yu O, Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk. J Am Geriatr Soc. 2018;66(2):247-253.
Gray SL, Anderson ML, Hanlon JT, Dublin S, Walker R, Hubbard, RA, Yu O, Montine T, Sonnen J, Keene CD, Crane PK, Larson EB. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. J Alzheimers Dis 2018;65(2):607-616.

Rachel Firebaugh

Education

PharmD, Pacific University
Master of Public Health, University of Montana
Bachelor of Arts in Psychology, University of Washington

Beth Devine

Education

MSc, Medical Statistics and Health Data Science, University of Bristol
Post-doctoral Fellowship, The CHOICE Institute, UW and Roche Global Pharma Business
PhD, Health Services Research, UW
MBA, University of San Francisco
PharmD, University of the Pacific
Clinical Pharmacy Residency, Palo Alto VA Medical Center

Research Interests

Evidence synthesis; systematic reviews, meta-analysis, network meta-analysis using Bayesian and frequentist methods.
Precision medicine: pharmacogenomics; genomic risk for hereditary cancers.
Health technology assessment and outcomes research including preference-based methods, discrete choice experiments and multi-criteria decision analysis.
Comparative effectiveness research in the context of clinical informatics.
Real world evidence of costs and outcomes.
Medication safety.

Biography

Beth Devine is Professor Emerita at The CHOICE Institute, School of Pharmacy Prior to becoming emerita, she held adjunct professorships in the Department of Health-Systems and Population Health, School of Public Health and the Department of Biomedical Informatics, School of Medicine.

She also held the Shirley and Herb Bridge Endowed Professor for Women in Pharmacy (2021-2023). She is currently a Visiting Professor at the University of Bristol, UK (2024-2026). She was a Fulbright US Scholar to the University of Murcia, Spain (2021-2022) and an Honorary Professor there (2022-2023).

She is currently president-elect of ISPOR – The Professional Society for Health Economics and Outcomes Research (2025-2026), was a member of the Board of Directors of ISPOR (2021-2024) and is an Associate Editor for the ISPOR journal Value in Health (2021-2029). She served on the ISPOR Task Force that developed guidelines to conduct network meta-analyses (2009-2011) and is currently co-chairing the ISPOR Task Force to update to these guidelines (2026). From 2014-2025 she served as an Assistant Director of the AHRQ-funded Pacific Northwest Evidence-based Practice Center. In 2013, she was elected as a member of the Society for Research Synthesis Methodology.

Prior to joining the faculty at the UW, Dr. Devine was an advanced practice (prescribing) clinical pharmacist and led the Pharmacy & Therapeutics Committee at the University of California San Francisco. where she served a term as president of the California Society of Health-System Pharmacists, earning their Lifetime Achievement Award for her leadership role in advancing the scope of practice for California pharmacists through legislation (1994).

Courses Taught

HEOR DS 510: Data Science in Health Economics and Outcomes Research
HECON 530 – Health Technology Assessment in a Global Environment
HEOR 531/HSERV 584 – Assessing Outcomes in Health & Medicine
PHRMCY 514 – Design and Analysis of Medical Studies

Selected Peer-Reviewed Publications

MyNCBI Bibliography
https://www.ncbi.nlm.nih.gov/myncbi/emily.devine.1/bibliography/public/

Google Scholar Profile: (n = 336; citations: 11294; h-index = 43, i10-index = 128)
https://scholar.google.com/citations?user=Wor4Qv0AAAAJ&hl=en

Karan Dawson

Education

PhD in Communication, University of Washington
Master of Science in Pharmacy (Minor in Business Administration), University of Washington
Bachelor of Science in Pharmacy, University of Washington

Research Interests

Education and professional development
Human behavior and communication
Geriatrics

Courses Taught

Pharm 584, 585, 586: Pharmacy Practice I, II and III
Pharm 532, PharmP 533: IPPE Hospital II and III

Biography

Following an internship at Valley Medical Center, Dr. Dawson worked as a clinical pharmacist at the Veterans Affairs (VA) Medical Center in Seattle, where she also completed a residency. She returned to the UW for an MS in Pharmacy to explore teaching and research, which led to becoming the director of continuing pharmacy education.

Dr. Dawson continued to pursue her interests in chronic diseases and substance abuse, areas of specialty developed during work at the VA. She was course master for the clinical therapeutics courses in both the School of Pharmacy and UW School of Nursing; managed the UW School of Pharmacy institutional clerkship program; and developed a number of electives including a first in tobacco cessation for teens run by pharmacy students and a self-care course for non-majors, which was aired on the UW educational television channel and included a live call-in show.

Given the changing needs of pharmacists to provide patient-centered care, she returned to the UW for a PhD in speech communication. She currently teaches in three pharmacy practice courses – a course for non-majors about medications and health; and a course in mind/body/medicine for graduate students in the health sciences.

She is one of three consulting pharmacists in an innovative, non-dispensing practice that serves retirement communities. She has won three awards for innovative teaching, served in a series of elective offices for the American Association of Colleges of Pharmacy, and continues to precept pharmacy clerkship students. Her current research interests are in the areas of teaching effectiveness, the provision of non-dispensing pharmacy services, and application of mind/body/spirit/medicine techniques to enhance professional self-care and patient well-being.

Anirban Basu

Education

PhD, Public Policy (Health Economics), University of Chicago, 2004
MS, Biostatistics, UNC-Chapel Hill, 1999
MS, Industrial Pharmacy, University of Toledo, 1997
BS, Pharmaceutical Technology, Jadavpur University India

Courses Taught

Welfare Economics foundations for cost-effectiveness analysis (HSERV 583, ’11 & ‘12) – 1.5 hour sessions
Understanding the role of uncertainty in decision models (HSERV 583, ’13 & ‘14) – 1.5 hour sessions
Quantitative methods for valuing information in health care (HSERV 584, ‘11) – 1.5 hour sessions
Introduction to comparative effectiveness methods (HSERV 523, ’11; HSERV 513 & HSERV 592, ’12) – 1.5 hour sessions
Instrumental variable methods (HSERV 523, ‘11) – 1.5 hour session
Financing healthcare (HuBio 555, ’13, ‘14) – 1.5 hour session to 250 2nd year medical students
Quantile regression methods (HSERV 525, ’11, HSERV 523, ‘12) – 1.5 hour sessions
Variations in healthcare spending: Observations & Implications (PHARM 568, ’14 -‘16) – 1.5 hour sessions
Causal inference in observational studies (HSERV 525), Spring 2013 -2019- Ten 3 hour sessions.

Research Interests

comparative and cost-effectiveness analyses
causal inference methods
program evaluation, and outcomes research

Biography

Anirban Basu, PhD, MS, is a health economist and a statistician who specializes in research on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research. He directs The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington, Seattle, with appointments in the departments of Pharmacy, Health Services, and Economics at the university. He is a Faculty Research Fellow at the National Bureau of Economic Research, and a Fellow of the American Statistical Association. He was one of the panelists for the Second Panel on the Cost-Effectiveness Analysis in Health and Medicine. He studies heterogeneity in clinical and economic outcomes, micro behavior with respect to heterogeneous information, and the value of individualized care. He teaches topics in health economics, decision analysis, cost-effectiveness analysis, and health services research methods. He received his PhD in Public Policy (Health Economics Specialization) from The University of Chicago and an MS in Biostatistics from the University of North Carolina at Chapel Hill. http://faculty.washington.edu/basua/

Selected Publications

https://scholar.google.com/citations?user=AR72duAAAAAJ&hl=en

Jennifer Bacci

Education:

PharmD, University of Pittsburgh School of Pharmacy
MPH, University of Pittsburgh School of Public Health

Research Interests:

Community-based pharmacy practice
Implementation science
Prevention and public health

Courses Taught:

PHRMCY 501: Foundations of Being a Pharmacist I
PHRMCY 502: Foundations of Being a Pharmacist II
PHARM 523: Insights into Community Pharmacy Practice Transformation

Biography:

Dr. Bacci is the Endowed Associate Professor of Innovative Pharmacy Practice at the University of Washington School of Pharmacy. Her research focuses on the application of implementation science to evaluate and advance the adoption of innovative patient care models in community pharmacy practice, including childhood and adult vaccinations, point-of-care testing, chronic disease management, pharmacist prescribing, and medical billing. Dr. Bacci collaborates closely with community partners to address needs and challenges faced by practitioners and patients and amplify the positive impact of community-based pharmacy teams.

Dr. Bacci practiced in community pharmacy for 10 years in chain and independent settings and is a Board Certified Ambulatory Care Pharmacist (BCACP). She remains highly engaged in practice as a member of the Washington State Pharmacy Association (WSPA) Board of Directors, a Network Facilitator for CPESN WA, a clinically integrated network of independent pharmacies in Washington State, and as a leader in the Academia-Community Transformation (ACT) Pharmacy Collaborative, a nationwide collaboration to support and facilitate community pharmacy practice transformation efforts.

Dr. Bacci has been honored with the 2021 Albert B. Prescott Pharmacy Leadership Award and 2019 Washington State Distinguished Young Pharmacist of the Year Award. Dr. Bacci and her research collaborators have been recognized with the 2018 NAIIS “Immunization Neighborhood” Adult Immunization Champion Award and 2018 American Pharmacist Association Immunization Champion Award.

Dr. Bacci completed her PharmD at PittPharmacy in 2011 followed by followed by a PGY-1 Community-based Pharmacy Residency with PittPharmacy and Rite Aid. After working full-time in community practice, she returned to PittPharmacy to complete a two-year Community Pharmacy Research Fellowship.

Selected Publications:

Wittenauer R, Shah PD, Bacci JL, Stergachis A. Locations and characteristics of pharmacy deserts in the United States: a geospatial study. Health Aff Sch. 2024;2(4):qxae035. Published 2024 Mar 16. doi:10.1093/haschl/qxae035

Bacci JL, English C, Odegard PS, Stergachis A, Snyder CR, Danielson JH. A 2023 Washington State pharmacist workforce survey: Employment and patient care roles. J Am Pharm Assoc (2003). 2025;65(1):102314. doi:10.1016/j.japh.2024.102314

Bacci JL, Nwogu IB, Zaraa S, et al. A community pharmacist intervention for people living with epilepsy. J Am Pharm Assoc (2003). 2025;65(1):102275. doi:10.1016/j.japh.2024.102275

Bhardwaj S, Galanter N, Berenbrok LA, Shah PD, Bacci JL. Pediatric vaccination in pharmacies is not associated with delayed well-child visits among commercially insured children. Health Aff Sch. 2025;3(2):qxaf028. Published 2025 Feb 10. doi:10.1093/haschl/qxaf028

Bacci JL, Marcum ZA, Rodriguez P, et al. Community pharmacist intervention to optimize statin adherence in diabetes care: The GuIDE-S study. J Am Pharm Assoc. 2023;63(3):946-951. doi:10.1016/j.japh.2023.03.002

Bacci JL, Rodriguez T, Hansen R, et al. Community pharmacist intervention to close statin gaps in diabetes care: The GuIDE-S study. J Am Pharm Assoc. 2023;63(1):108-117. doi:10.1016/j.japh.2022.08.025

Bacci JL, Coley K, Daly C, et al. Qualitative analysis of community pharmacy practice transformation. J Am Coll Clin Pharm. 2022; 5(12):1236-1252. doi:10.1002/jac5.1728

Bacci JL, Odegard P, Arnold J, Stergachis A. Strengthening pandemic preparedness through pharmacy and public health collaborations: Findings from a facilitated discussion exercise. J Am Pharm Assoc. 2021;61(3):e99-e106. doi:10.1016/j.japh.2020.12.024

Bacci JL, Zaraa S, Stergachis A, Simic G, White HS. Community pharmacists’ role in caring for people living with epilepsy: A scoping review. Epilepsy Behav. 2021;117:107850. doi:10.1016/j.yebeh.2021.107850

Bacci JL, Hansen R, Ree C, Reynolds MJ, Stergachis A, Odegard PS. The effects of vaccination forecasts and value-based payment on adult immunizations by community pharmacists. Vaccine. 2019;37(1):152-159. doi:10.1016/j.vaccine.2018.11.018

Wang AB, Bacci JL, Amoo M, Ree C, Firebaugh R, Odegard P. Impact of an immunization platform in community pharmacies. J Am Pharm Assoc. 2019;59(4S):S151-S155. doi:10.1016/j.japh.2019.05.007

Akers JL, Meer G, Kintner J, Shields A, Dillon-Sumner L, Bacci JL. Implementing a pharmacist-led in-home medication coaching service via community-based partnerships. J Am Pharm Assoc. 2019;59(2):243-251. doi:10.1016/j.japh.2018.11.008

Melissa Barker-Haliski

Education:

BA – University of Oregon
Ph.D. – University of Utah

Research Interests:

Epilepsy
Alzheimer’s disease
drug development
preclinical research
translational research
neuroscience
pharmacology

Courses Taught:

PCEUT 451/551 – Introduction to Drug Discovery
PCEUT 534 – Principles of Precision Medicine
PCEUT 540 – Communication for Pharmaceutical Sciences

Biography:

Dr. Melissa Barker-Haliski’s research emphasizes developing novel strategies and preclinical approaches to uncover precision medicine therapies for unmet medical needs for people with epilepsy and for seizures related to neurodegenerative disease, including Alzheimer’s disease. Using behavioral models and molecular neuroscience, the lab is particularly interested in therapeutic discovery and neuropharmacological interactions to modify disease trajectory. She served as co-chair of the American Epilepsy Society/International League Against Epilepsy (ILAE) Pharmacology Common Data Elements Working Group (2014–2018) and the Phenotyping Common Data Elements Working Group (2019–2022), helping to standardize preclinical pharmacology research across industry, government, and academia. She is current co-chair of the ILAE Precision Therapy for Epilepsy Task Force. Dr. Barker-Haliski actively engages with industry and government leaders to drive next-generation therapeutic discovery for neurological disease.

Publications:

Smith VL, Gidi BZ, Bragg RM, Cantle JP, Ben-Varon A, Noble B, Prades S, Compton A, Greenfield J, Korecka JA, Gemos A, Yu T, Khurana V, Kordasiewicz HB, Zhao HT, Barker-Haliski M, Child DD, Carroll JB. Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model. Mol Ther Nucleic Acids. 2025 Dec 31;37(1):102815. doi: 10.1016/j.omtn.2025.102815. PMID: 41624332; PMCID: PMC12857545.

Robinson-Cooper L, Davidson S, Koutoubi R, Zhang K, Park H, Barker-Haliski M. Loss of presenilin 2 function age-dependently increases susceptibility to kainate-induced acute seizures and blunts hippocampal kainate-type glutamate receptor expression. Exp Neurol. 2026 Mar;397:115586. doi: 10.1016/j.expneurol.2025.115586. Epub 2025 Dec 9. PMID: 41380794; PMCID: PMC12799287.

Knox KM, Davidson S, Lehmann LM, Skinner E, Lo A, Jayadev S, Barker-Haliski M. Alzheimer’s disease-associated genotypes differentially influence chronic evoked seizure outcomes and antiseizure medicine efficacy in aged mice. J Alzheimers Dis. 2025 Jul;106(2):547-561. doi: 10.1177/13872877251343321. Epub 2025 Jul 1. PMID: 40458037; PMCID: PMC12282399.

Erickson I, Davidson S, Choi H, Rho S, Guignet M, Peagler K, Thummel K, Ericsson A, Barker-Haliski M. Intestinal dysbiosis alters acute seizure burden and antiseizure medicine activity in Theiler’s virus model of encephalitis. Epilepsia. 2025 Aug;66(8):3022-3034. doi: 10.1111/epi.18395. Epub 2025 Mar 28. PMID: 40153196.

Del Pozo A, Knox KM, Lehmann LM, Davidson S, Rho SL, Jayadev S, Barker-Haliski M. Chronic evoked seizures in young pre-symptomatic APP/PS1 mice induce serotonin changes and accelerate onset of Alzheimer’s disease-related neuropathology. Prog Neurobiol. 2024 Apr;235:102591. doi: 10.1016/j.pneurobio.2024.102591. Epub 2024 Mar 13. PMID: 38484965; PMCID: PMC11015961.

Abhinav Nath

Accepting Students to Lab: Yes

Education

B.A. (Chemistry and Biology), University of Virginia
Ph.D. (Medicinal Chemistry/Biomolecular Structure & Design), University of Washington
Postdoc (Molecular Biophysics & Biochemistry), Yale University

Research Interests

Protein aggregation in Alzheimer’s disease and related dementias
Protein self-assembly
Biologics and protein-based therapeutics

Biography

Abhinav “Abhi” Nath earned his BA (in Biology and Chemistry) from the University of Virginia in 2003, and his PhD (in Medicinal Chemistry and Biomolecular Structure & Design) from the University of Washington in 2008, where he worked with Bill Atkins on understanding the mechanisms of substrate binding by cytochrome P450s and other drug-metabolizing enzymes. He then moved to Yale University for postdoctoral training with professors Liz Rhoades and Andrew Miranker, where he was an American Heart Association Postdoctoral Fellow and studied intrinsically disordered and amyloid-forming proteins using single-molecule fluorescence and computational methods.

The Nath lab is interested in understanding the roles of protein dynamics in human health and disease. Proteins display a fascinating spectrum of dynamic behavior, ranging from some that are almost static to others that rapidly interconvert between a diverse ensemble of structures. The nature, amplitude and timescales of protein conformational fluctuations can be crucial to biological functions such as enzyme catalysis and intracellular signaling. Mutations, post-translational modifications and environmental factors can perturb protein dynamics – and hence normal function – in ways that are difficult to predict.

Abhi and his group are developing new and powerful methods to characterize and control protein dynamics, building on recent advances in biophysics, biochemistry and pharmacology from groups around the world. They focus on proteins involved in degenerative disorders (such as Alzheimer’s disease), the oxidative stress response, and drug metabolism.

Recent Publications

Rigorous Analysis of Multimodal HDX-MS Spectra. Tuttle LM, James EI, Georgescauld F, Wales TE, Weis DD, Engen JR, Nath A, Klevit RE, Guttman M. J Am Soc Mass Spectrom. 2025 Feb 5;36(2):416-423.

Drugs Form Ternary Complexes with Human Liver Fatty Acid Binding Protein (FABP1) and FABP1 Binding Alters Drug Metabolism. Yabut KCB, Martynova A, Nath A, Zercher BP, Bush MF, Isoherranen N. Mol Pharmacol. 2024 Apr 5:MOLPHARM-AR-2024-000878.

Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review. Wiley AM, Yang J, Madhani R, Nath A, Totah RA. Drug Metab Rev. 2024 Mar 20:1-19.

Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation. James EI, Baggett DW, Chang E, Schachter J, Nixey T, Choi K, Guttman M, Nath A. bioRxiv [Preprint]. 2024 Feb 3:2024.02.02.578649.

The origins of nonideality exhibited by monoclonal antibodies and Fab fragments in human serum. Larsen HA, Atkins WM, Nath A. Protein Sci. 2023 Dec;32(12):e4812.

The Utility of Mixed Effects Models in the Evaluation of Complex Genomic Traits In Vitro. Alade N, Nath A, Isoherranen N, Thummel KE. Drug Metab Dispos. 2023 Nov;51(11):1455-1462.

Low molecular weight ligands bind to CYP3A4 via a branched induced fit mechanism: Implications for O₂ binding. Redhair M, Nath A, Hackett JC, Atkins WM. Arch Biochem Biophys. 2023 May 1;739:109582.

MitoNEET’s Reactivity of Lys55 toward Pyridoxal Phosphate Demonstrates its Activity as a Transaminase Enzyme. Kunk C, Kruger J, Mendoza G, Markitan J, Bias T, Mann A, Nath A, Geldenhuys WJ, Menze MA, Konkle ME. ACS Chem Biol. 2022 Oct 21;17(10):2716-2722.

Structure-Activity Relationships of Novel Tau Ligands: Passive Fibril Binders and Active Aggregation Inhibitors. Baggett DW, Nath A. ACS Chem Biol. 2022 Mar 18;17(3):701-708.

PI Association	PMID	Publication Year	First Author	Title	Citation	DOI	Link	Updated
Nath	36194135	2022	Kunk C	MitoNEET's Reactivity of Lys55 toward Pyridoxal Phosphate Demonstrates its Activity as a Transaminase Enzyme	ACS Chem Biol. 2022 Oct 21;17(10):2716-2722. doi: 10.1021/acschembio.2c00572. Epub 2022 Oct 4.	10.1021/acschembio.2c00572	https://doi.org/10.1021/acschembio.2c00572
Nath	38352474	2024	James EI	Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation	bioRxiv [Preprint]. 2024 Feb 3:2024.02.02.578649. doi: 10.1101/2024.02.02.578649.	10.1101/2024.02.02.578649	https://doi.org/10.1101/2024.02.02.578649
Nath	37861473	2023	Larsen HA	The origins of nonideality exhibited by monoclonal antibodies and Fab fragments in human serum	Protein Sci. 2023 Dec;32(12):e4812. doi: 10.1002/pro.4812.	10.1002/pro.4812	https://doi.org/10.1002/pro.4812
Nath	37562955	2023	Alade N	The Utility of Mixed Effects Models in the Evaluation of Complex Genomic Traits In Vitro	Drug Metab Dispos. 2023 Nov;51(11):1455-1462. doi: 10.1124/dmd.123.001260. Epub 2023 Aug 10.	10.1124/dmd.123.001260	https://doi.org/10.1124/dmd.123.001260
Nath	36948348	2023	Redhair M	Low molecular weight ligands bind to CYP3A4 via a branched induced fit mechanism: Implications for O(2) binding	Arch Biochem Biophys. 2023 May 1;739:109582. doi: 10.1016/j.abb.2023.109582. Epub 2023 Mar 21.	10.1016/j.abb.2023.109582	https://doi.org/10.1016/j.abb.2023.109582
Nath	34384764	2021	Larsen HA	Probing interactions of therapeutic antibodies with serum via second virial coefficient measurements	Biophys J. 2021 Sep 21;120(18):4067-4078. doi: 10.1016/j.bpj.2021.08.007. Epub 2021 Aug 10.	10.1016/j.bpj.2021.08.007	https://doi.org/10.1016/j.bpj.2021.08.007
Nath	41279711	2025	James EI	Tau4RD fibril polymorphism is imprinted during early aggregation	bioRxiv [Preprint]. 2025 Oct 14:2025.10.12.681486. doi: 10.1101/2025.10.12.681486.	10.1101/2025.10.12.681486	https://doi.org/10.1101/2025.10.12.681486
Nath	32814060	2020	Vane EW	Rapid Formation of Peptide/Lipid Coaggregates by the Amyloidogenic Seminal Peptide PAP(248-286)	Biophys J. 2020 Sep 1;119(5):924-938. doi: 10.1016/j.bpj.2020.07.029. Epub 2020 Aug 6.	10.1016/j.bpj.2020.07.029	https://doi.org/10.1016/j.bpj.2020.07.029
Nath	31974309	2020	Baughman HER	Release of a disordered domain enhances HspB1 chaperone activity toward tau	Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2923-2929. doi: 10.1073/pnas.1915099117. Epub 2020 Jan 23.	10.1073/pnas.1915099117	https://doi.org/10.1073/pnas.1915099117
Nath	33057715	2021	Shen T	Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage	J Antimicrob Chemother. 2021 Jan 19;76(2):292-296. doi: 10.1093/jac/dkaa422.	10.1093/jac/dkaa422	https://doi.org/10.1093/jac/dkaa422
Nath	38293009	2024	Yabut KCB	Drugs Form Ternary Complexes with Human Liver Fatty Acid Binding Protein (FABP1) and FABP1 Binding Alters Drug Metabolism	bioRxiv [Preprint]. 2024 Jan 19:2024.01.17.576032. doi: 10.1101/2024.01.17.576032.	10.1101/2024.01.17.576032	https://doi.org/10.1101/2024.01.17.576032
Nath	38580446	2024	Yabut KCB	Drugs Form Ternary Complexes with Human Liver Fatty Acid Binding Protein 1 (FABP1) and FABP1 Binding Alters Drug Metabolism	Mol Pharmacol. 2024 May 17;105(6):395-410. doi: 10.1124/molpharm.124.000878.	10.1124/molpharm.124.000878	https://doi.org/10.1124/molpharm.124.000878
Nath	33161206	2021	Sager JE	Corrigendum to "In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation" [Biochem. Pharmacol. 123(2017)85-96]	Biochem Pharmacol. 2021 Jan;183:114306. doi: 10.1016/j.bcp.2020.114306. Epub 2020 Nov 5.	10.1016/j.bcp.2020.114306	https://doi.org/10.1016/j.bcp.2020.114306
Atkins	31961139	2020	Redhair M	Dynamics and Location of the Allosteric Midazolam Site in Cytochrome P4503A4 in Lipid Nanodiscs	Biochemistry. 2020 Feb 18;59(6):766-779. doi: 10.1021/acs.biochem.9b01001. Epub 2020 Jan 27.	10.1021/acs.biochem.9b01001	https://doi.org/10.1021/acs.biochem.9b01001
Atkins	31982812	2020	Lockart MM	Multiple drug binding modes in Mycobacterium tuberculosis CYP51B1	J Inorg Biochem. 2020 Apr;205:110994. doi: 10.1016/j.jinorgbio.2020.110994. Epub 2020 Jan 13.	10.1016/j.jinorgbio.2020.110994	https://doi.org/10.1016/j.jinorgbio.2020.110994
Atkins	32786398	2020	PaÃÂÃÂ§o L	Dynamics and Mechanism of Binding of Androstenedione to Membrane-Associated Aromatase	Biochemistry. 2020 Aug 25;59(33):2999-3009. doi: 10.1021/acs.biochem.0c00460. Epub 2020 Aug 11.	10.1021/acs.biochem.0c00460	https://doi.org/10.1021/acs.biochem.0c00460
Atkins	33350827	2021	Clouser AF	Cholesterol Asymmetrically Modulates the Conformational Ensemble of the Nucleotide-Binding Domains of P-Glycoprotein in Lipid Nanodiscs	Biochemistry. 2021 Jan 12;60(1):85-94. doi: 10.1021/acs.biochem.0c00824. Epub 2020 Dec 22.	10.1021/acs.biochem.0c00824	https://doi.org/10.1021/acs.biochem.0c00824
Atkins	34715072	2021	Redhair M	Analytical and functional aspects of protein-ligand interactions: Beyond induced fit and conformational selection	Arch Biochem Biophys. 2021 Dec 15;714:109064. doi: 10.1016/j.abb.2021.109064. Epub 2021 Oct 26.	10.1016/j.abb.2021.109064	https://doi.org/10.1016/j.abb.2021.109064
Atkins	35384651	2022	Clouser AF	Long Range Communication between the Drug-Binding Sites and Nucleotide Binding Domains of the Efflux Transporter ABCB1	Biochemistry. 2022 Apr 19;61(8):730-740. doi: 10.1021/acs.biochem.2c00056. Epub 2022 Apr 6.	10.1021/acs.biochem.2c00056	https://doi.org/10.1021/acs.biochem.2c00056
Atkins	37080138	2023	PaÃÂÃÂ§o L	Nanodisc-embedded cytochrome P450 P3A4 binds diverse ligands by distributing conformational dynamics to its flexible elements	J Inorg Biochem. 2023 Jul;244:112211. doi: 10.1016/j.jinorgbio.2023.112211. Epub 2023 Apr 5.	10.1016/j.jinorgbio.2023.112211	https://doi.org/10.1016/j.jinorgbio.2023.112211
Atkins	36948348	2023	Redhair M	Low molecular weight ligands bind to CYP3A4 via a branched induced fit mechanism: Implications for O(2) binding	Arch Biochem Biophys. 2023 May 1;739:109582. doi: 10.1016/j.abb.2023.109582. Epub 2023 Mar 21.	10.1016/j.abb.2023.109582	https://doi.org/10.1016/j.abb.2023.109582
Atkins	31173761	2020	Goulet DR	Considerations for the Design of Antibody-Based Therapeutics	J Pharm Sci. 2020 Jan;109(1):74-103. doi: 10.1016/j.xphs.2019.05.031. Epub 2019 Jun 4.	10.1016/j.xphs.2019.05.031	https://doi.org/10.1016/j.xphs.2019.05.031
Atkins	31702857	2020	Goulet DR	Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors	Proteins. 2020 May;88(5):689-697. doi: 10.1002/prot.25853. Epub 2019 Nov 20.	10.1002/prot.25853	https://doi.org/10.1002/prot.25853
Atkins	34383776	2021	Kachapila M	Preliminary model assessing the cost-effectiveness of preoperative chlorhexidine mouthwash at reducing postoperative pneumonia among abdominal surgery patients in South Africa	PLoS One. 2021 Aug 12;16(8):e0254698. doi: 10.1371/journal.pone.0254698. eCollection 2021.	10.1371/journal.pone.0254698	https://doi.org/10.1371/journal.pone.0254698
Atkins	34384764	2021	Larsen HA	Probing interactions of therapeutic antibodies with serum via second virial coefficient measurements	Biophys J. 2021 Sep 21;120(18):4067-4078. doi: 10.1016/j.bpj.2021.08.007. Epub 2021 Aug 10.	10.1016/j.bpj.2021.08.007	https://doi.org/10.1016/j.bpj.2021.08.007
Atkins	34871379	2021	STARSurg Collaborative and COVIDSurg Collaborative	Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic	Br J Surg. 2021 Dec 1;108(12):1448-1464. doi: 10.1093/bjs/znab336.	10.1093/bjs/znab336	https://doi.org/10.1093/bjs/znab336
Atkins	35750401	2022	STARSurg Collaborative and TASMAN Collaborative	Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study	Lancet Digit Health. 2022 Jul;4(7):e520-e531. doi: 10.1016/S2589-7500(22)00069-3.	10.1016/S2589-7500(22)00069-3	https://doi.org/10.1016/s2589-7500(22)00069-3
Atkins	31663687	2020	Atkins WM	Mechanisms of promiscuity among drug metabolizing enzymes and drug transporters	FEBS J. 2020 Apr;287(7):1306-1322. doi: 10.1111/febs.15116. Epub 2019 Nov 12.	10.1111/febs.15116	https://doi.org/10.1111/febs.15116
Atkins	36830698	2023	Scian M	Reversibility and Low Commitment to Forward Catalysis in the Conjugation of Lipid Alkenals by Glutathione Transferase A4-4	Biomolecules. 2023 Feb 9;13(2):329. doi: 10.3390/biom13020329.	10.3390/biom13020329	https://doi.org/10.3390/biom13020329
Atkins	37861473	2023	Larsen HA	The origins of nonideality exhibited by monoclonal antibodies and Fab fragments in human serum	Protein Sci. 2023 Dec;32(12):e4812. doi: 10.1002/pro.4812.	10.1002/pro.4812	https://doi.org/10.1002/pro.4812
Bhardwaj	42056544	2026	Yang W	The past, present and future of de novo protein design	Yang W, Wang S, Lee GR, Zhang JZ, Courbet A, Juergens D, Wang X, Schlichthaerle T, Abedi M, Ragotte R, An L, Kalvet I, Pellock S, Mihaljevic L, Glasscock C, Pillai A, Broerman A, Ennist N, Haefner E, McNamara-Bordewick N, Haydon I, Stewart L, Bhardwaj G, Baker D. The past, present and future of de novo protein design. Nature. 2026 Apr;652(8112):1139-1152. doi: 10.1038/s41586-026-10328-7. Epub 2026 Apr 29. PMID: 42056544.	10.1038/s41586-026-10328-7	https://doi.org/10.1038/s41586-026-10328-7
Bhardwaj	41818167	2026	Luxford JC,	Mixed Autoimmune Hemolytic Anemia With Refractory Cold Agglutinin Syndrome in a Child Successfully Treated With Serial Whole Blood Exchange Transfusions and Immunosuppression	Luxford JC, Quadir A, Jatana V, Birman C, Bhardwaj G, Woods A, Teo J. Mixed Autoimmune Hemolytic Anemia With Refractory Cold Agglutinin Syndrome in a Child Successfully Treated With Serial Whole Blood Exchange Transfusions and Immunosuppression. J Pediatr Hematol Oncol. 2026 Apr 1;48(3):e128-e133. doi: 10.1097/MPH.0000000000003180. Epub 2026 Mar 2.	10.1097/MPH.0000000000003180	https://doi.org/10.1097/mph.0000000000003180	4/28/26
Bhardwaj	41779186	2026	Wankhede L	Integrated one-pot ultrasound-assisted method for carotenoid extraction from Rhodosporidium toruloides	Wankhede L, Bhardwaj G, Osorio-GonzÃÂÃÂ¡lez CS, Brar SK. Integrated one-pot ultrasound-assisted method for carotenoid extraction from Rhodosporidium toruloides. Bioprocess Biosyst Eng. 2026 Mar 4. doi: 10.1007/s00449-026-03299-6. Epub ahead of print.	10.1007/s00449-026-03299-6	https://doi.org/10.1007/s00449-026-03299-6	4/28/26
Bhardwaj	36384286	2023	Manna P	Accommodative spasm and its different treatment approaches: A systematic review	Eur J Ophthalmol. 2023 May;33(3):1273-1286. doi: 10.1177/11206721221136438. Epub 2022 Nov 16.	10.1177/11206721221136438	https://doi.org/10.1177/11206721221136438
Bhardwaj	36041435	2022	Bhardwaj G	Accurate de novo design of membrane-traversing macrocycles	Cell. 2022 Sep 15;185(19):3520-3532.e26. doi: 10.1016/j.cell.2022.07.019. Epub 2022 Aug 29.	10.1016/j.cell.2022.07.019	https://doi.org/10.1016/j.cell.2022.07.019
Bhardwaj	36865323	2023	Rettie SA	Cyclic peptide structure prediction and design using AlphaFold	bioRxiv [Preprint]. 2023 Feb 26:2023.02.25.529956. doi: 10.1101/2023.02.25.529956.	10.1101/2023.02.25.529956	https://doi.org/10.1101/2023.02.25.529956
Bhardwaj	39605685	2024	Rettie SA	Accurate de novo design of high-affinity protein binding macrocycles using deep learning	bioRxiv [Preprint]. 2024 Nov 18:2024.11.18.622547. doi: 10.1101/2024.11.18.622547.	10.1101/2024.11.18.622547	https://doi.org/10.1101/2024.11.18.622547
Bhardwaj	40542165	2025	Rettie SA	Accurate de novo design of high-affinity protein-binding macrocycles using deep learning	Nat Chem Biol. 2025 Dec;21(12):1948-1956. doi: 10.1038/s41589-025-01929-w. Epub 2025 Jun 20.	10.1038/s41589-025-01929-w	https://doi.org/10.1038/s41589-025-01929-w
Bhardwaj	39525204	2024	Mahajan BB	Bilastine Reimagined: A Comprehensive Exploration of Pruritus Management With a Novel Antihistamine	Cureus. 2024 Oct 10;16(10):e71232. doi: 10.7759/cureus.71232. eCollection 2024 Oct.	10.7759/cureus.71232	https://doi.org/10.7759/cureus.71232
Bhardwaj	38052802	2023	MuratspahiÃÂÃÂ E	Design and structural validation of peptide-drug conjugate ligands of the kappa-opioid receptor	Nat Commun. 2023 Dec 6;14(1):8064. doi: 10.1038/s41467-023-43718-w.	10.1038/s41467-023-43718-w	https://doi.org/10.1038/s41467-023-43718-w
Bhardwaj	40399308	2025	Rettie SA	Cyclic peptide structure prediction and design using AlphaFold2	Nat Commun. 2025 May 21;16(1):4730. doi: 10.1038/s41467-025-59940-7.	10.1038/s41467-025-59940-7	https://doi.org/10.1038/s41467-025-59940-7
Bhardwaj	39618904	2024	Mondal A	Binocular Vision Status in Coal Miners	Indian J Occup Environ Med. 2024 Jul-Sep;28(3):194-197. doi: 10.4103/ijoem.ijoem_137_23. Epub 2024 Sep 30.	10.4103/ijoem.ijoem_137_23	https://doi.org/10.4103/ijoem.ijoem_137_23
Bhardwaj	37178478	2023	Ramelot TA	Cell-permeable chameleonic peptides: Exploiting conformational dynamics in de novo cyclic peptide design	Curr Opin Struct Biol. 2023 Jun;80:102603. doi: 10.1016/j.sbi.2023.102603. Epub 2023 May 12.	10.1016/j.sbi.2023.102603	https://doi.org/10.1016/j.sbi.2023.102603
Bhardwaj	39032267	2024	Wankhede L	Technological modes and processes to enhance the Rhodosporidium toruloides based lipid accumulation	Microbiol Res. 2024 Oct;287:127840. doi: 10.1016/j.micres.2024.127840. Epub 2024 Jul 16.	10.1016/j.micres.2024.127840	https://doi.org/10.1016/j.micres.2024.127840
Bhardwaj	35112543	2021	Naredi M	Diabetic myonecrosis in end-stage renal disease	Natl Med J India. 2021 Jul-Aug;34(4):206-210. doi: 10.25259/NMJI_191_19.	10.25259/NMJI_191_19	https://doi.org/10.25259/nmji_191_19
Bhardwaj	38662830	2024	Salveson PJ	Expansive discovery of chemically diverse structured macrocyclic oligoamides	Science. 2024 Apr 26;384(6694):420-428. doi: 10.1126/science.adk1687. Epub 2024 Apr 25.	10.1126/science.adk1687	https://doi.org/10.1126/science.adk1687
Bhardwaj	41117072	2025	Gokce-Alpkilic G	De Novo Design of High-Affinity Miniprotein Binders Targeting Francisella Tularensis Virulence Factor	Angew Chem Int Ed Engl. 2025 Dec 22;64(52):e202516058. doi: 10.1002/anie.202516058. Epub 2025 Oct 21.	10.1002/anie.202516058	https://doi.org/10.1002/anie.202516058
Bhardwaj	40631088	2025	Gokce-Alpkilic G	De novo design of high-affinity miniprotein binders targeting Francisella tularensis virulence factor	bioRxiv [Preprint]. 2025 Jul 5:2025.07.02.662053. doi: 10.1101/2025.07.02.662053.	10.1101/2025.07.02.662053	https://doi.org/10.1101/2025.07.02.662053
Bhardwaj	37780187	2023	Azam R	The Effect of Illumination on Positive Fusional Vergence	Br Ir Orthopt J. 2023 Sep 29;19(1):78-84. doi: 10.22599/bioj.296. eCollection 2023.	10.22599/bioj.296	https://doi.org/10.22599/bioj.296
Bhardwaj	39154992	2024	Mathew J	Innovating Ferro-sonication approach for extracting microplastics from wastewater	Sci Total Environ. 2024 Nov 15;951:175595. doi: 10.1016/j.scitotenv.2024.175595. Epub 2024 Aug 16.	10.1016/j.scitotenv.2024.175595	https://doi.org/10.1016/j.scitotenv.2024.175595
Bhardwaj	40357425	2025	Schumacher I	Performance analysis of an emergency triage system in ophthalmology using a customized CHATBOT	Digit Health. 2025 May 11;11:20552076251320298. doi: 10.1177/20552076251320298. eCollection 2025 Jan-Dec.	10.1177/20552076251320298	https://doi.org/10.1177/20552076251320298
Bhardwaj	38712757	2024	Craven TW	Computational Design of Cyclic Peptide Inhibitors of a Bacterial Membrane Lipoprotein Peptidase	ACS Chem Biol. 2024 May 17;19(5):1125-1130. doi: 10.1021/acschembio.4c00076. Epub 2024 May 7.	10.1021/acschembio.4c00076	https://doi.org/10.1021/acschembio.4c00076
Bhardwaj	38529717	2024	Bruce A	A Tag-Free Platform for Synthesis and Screening of Cyclic Peptide Libraries	Angew Chem Int Ed Engl. 2024 May 21;63(21):e202320045. doi: 10.1002/anie.202320045. Epub 2024 Apr 17.	10.1002/anie.202320045	https://doi.org/10.1002/anie.202320045
Bhardwaj	40666773	2025	Karmakar S	Cognitive decline, dual sensory loss and the use of visual aids in elderly - A narrative review	Oman J Ophthalmol. 2025 Jun 24;18(2):113-120. doi: 10.4103/ojo.ojo_177_23. eCollection 2025 May-Aug.	10.4103/ojo.ojo_177_23	https://doi.org/10.4103/ojo.ojo_177_23
Bhardwaj	32195445	2020	Bloch E	Scleral perforation involving the papillomacular bundle secondary to peribulbar anaesthetic injection	Am J Ophthalmol Case Rep. 2020 Mar 11;18:100657. doi: 10.1016/j.ajoc.2020.100657. eCollection 2020 Jun.	10.1016/j.ajoc.2020.100657	https://doi.org/10.1016/j.ajoc.2020.100657
Bhardwaj	32734467	2021	Anguita R	Clinical presentations and surgical outcomes of intraocular foreign body presenting to an ocular trauma unit	Graefes Arch Clin Exp Ophthalmol. 2021 Jan;259(1):263-268. doi: 10.1007/s00417-020-04859-6. Epub 2020 Jul 30.	10.1007/s00417-020-04859-6	https://doi.org/10.1007/s00417-020-04859-6
Bhardwaj	39406662	2024	Mathew J	Corrigendum to "Innovating Ferro-sonication approach for extracting microplastics from wastewater" [Sci. Total Environ. (2024) 1-9, 175595]	Sci Total Environ. 2024 Dec 1;954:176771. doi: 10.1016/j.scitotenv.2024.176771. Epub 2024 Oct 15.	10.1016/j.scitotenv.2024.176771	https://doi.org/10.1016/j.scitotenv.2024.176771
Bhardwaj	30576303	2020	Bhardwaj G	MANAGEMENT OF GIANT RETINAL TEARS USING TRANSSCLERAL DIODE LASER RETINOPEXY AND SHORT-TERM POSTOPERATIVE TAMPONADE WITH PERFLUORO-N-OCTANE	Retina. 2020 Mar;40(3):546-551. doi: 10.1097/IAE.0000000000002424.	10.1097/IAE.0000000000002424	https://doi.org/10.1097/iae.0000000000002424
Bhardwaj	39254187	2025	Manna P	Effects of Two Vision Therapy Approaches on Accommodative Insufficiency and Post-therapy Stability	J Pediatr Ophthalmol Strabismus. 2025 Jan-Feb;62(1):12-26. doi: 10.3928/01913913-20240807-01. Epub 2024 Sep 10.	10.3928/01913913-20240807-01	https://doi.org/10.3928/01913913-20240807-01
Bhardwaj	33391591	2020	Merkin R	Internal Medicine Resident Work Absence During the COVID-19 Pandemic at a Large Academic Medical Center in New York City	J Grad Med Educ. 2020 Dec;12(6):682-685. doi: 10.4300/JGME-D-20-00657.1. Epub 2020 Oct 20.	10.4300/JGME-D-20-00657.1	https://doi.org/10.4300/jgme-d-20-00657.1
Bhardwaj	39801888	2025	Bhardwaj G	Successful Treatment of Chronic Wound in a Patient with Longstanding Shell Injury on Heel using, a Novel Product Formulation: A Case Report	J Orthop Case Rep. 2025 Jan;15(1):17-20. doi: 10.13107/jocr.2025.v15.i01.5108.	10.13107/jocr.2025.v15.i01.5108	https://doi.org/10.13107/jocr.2025.v15.i01.5108
Bhardwaj	34926053	2021	Masood S	Neuroendocrine Carcinoma of the Colon: Emergency Presentation of a Rare Disease With Poor Biology	Cureus. 2021 Nov 14;13(11):e19582. doi: 10.7759/cureus.19582. eCollection 2021 Nov.	10.7759/cureus.19582	https://doi.org/10.7759/cureus.19582
Guttman	33762730	2021	Boyoglu-Barnum S	Quadrivalent influenza nanoparticle vaccines induce broad protection	Nature. 2021 Apr;592(7855):623-628. doi: 10.1038/s41586-021-03365-x. Epub 2021 Mar 24.	10.1038/s41586-021-03365-x	https://doi.org/10.1038/s41586-021-03365-x
Guttman	33160446	2020	Walls AC	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2	Cell. 2020 Nov 25;183(5):1367-1382.e17. doi: 10.1016/j.cell.2020.10.043. Epub 2020 Oct 31.	10.1016/j.cell.2020.10.043	https://doi.org/10.1016/j.cell.2020.10.043
Guttman	39504958	2024	Cao S	Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress	Cell. 2024 Dec 26;187(26):7568-7584.e22. doi: 10.1016/j.cell.2024.10.012. Epub 2024 Nov 5.	10.1016/j.cell.2024.10.012	https://doi.org/10.1016/j.cell.2024.10.012
Guttman	40154915	2025	Watson MJ	Defining the Features of Complement-Active IgM	J Mol Biol. 2025 Jun 15;437(12):169104. doi: 10.1016/j.jmb.2025.169104. Epub 2025 Mar 26.	10.1016/j.jmb.2025.169104	https://doi.org/10.1016/j.jmb.2025.169104
Guttman	33350817	2021	Mookherjee A	Linkage Memory in Underivatized Protonated Carbohydrates	J Am Soc Mass Spectrom. 2021 Feb 3;32(2):581-589. doi: 10.1021/jasms.0c00440. Epub 2020 Dec 22.	10.1021/jasms.0c00440	https://doi.org/10.1021/jasms.0c00440
Guttman	40196533	2025	Ferrari ÃÂÃÂJR	Large-scale discovery, analysis, and design of protein energy landscapes	bioRxiv [Preprint]. 2025 Mar 25:2025.03.20.644235. doi: 10.1101/2025.03.20.644235.	10.1101/2025.03.20.644235	https://doi.org/10.1101/2025.03.20.644235
Guttman	34493042	2022	James EI	Advances in Hydrogen/Deuterium Exchange Mass Spectrometry and the Pursuit of Challenging Biological Systems	Chem Rev. 2022 Apr 27;122(8):7562-7623. doi: 10.1021/acs.chemrev.1c00279. Epub 2021 Sep 7.	10.1021/acs.chemrev.1c00279	https://doi.org/10.1021/acs.chemrev.1c00279
Guttman	39837577	2025	Tuttle LM	Rigorous Analysis of Multimodal HDX-MS Spectra	J Am Soc Mass Spectrom. 2025 Feb 5;36(2):416-423. doi: 10.1021/jasms.4c00471. Epub 2025 Jan 21.	10.1021/jasms.4c00471	https://doi.org/10.1021/jasms.4c00471
Guttman	32649906	2020	Potter ZE	Parallel Chemoselective Profiling for Mapping Protein Structure	Cell Chem Biol. 2020 Aug 20;27(8):1084-1096.e4. doi: 10.1016/j.chembiol.2020.06.014. Epub 2020 Jul 9.	10.1016/j.chembiol.2020.06.014	https://doi.org/10.1016/j.chembiol.2020.06.014
Guttman	40377988	2025	Woods CN	Activation mechanism of small heat shock protein HSPB5 revealed by disease-associated mutants	Proc Natl Acad Sci U S A. 2025 May 20;122(20):e2425061122. doi: 10.1073/pnas.2425061122. Epub 2025 May 16.	10.1073/pnas.2425061122	https://doi.org/10.1073/pnas.2425061122
Guttman	36719917	2023	Woods CN	Disordered region encodes ÃÂÃÂ±-crystallin chaperone activity towardÃÂÃÂ lens client ÃÂÃÂ³D-crystallin	Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2213765120. doi: 10.1073/pnas.2213765120. Epub 2023 Jan 31.	10.1073/pnas.2213765120	https://doi.org/10.1073/pnas.2213765120
Guttman	39434663	2024	Vorauer C	Direct Mapping of Polyclonal Epitopes in Serum by HDX-MS	Anal Chem. 2024 Oct 22;96(42):16758-16767. doi: 10.1021/acs.analchem.4c03274. Epub 2024 Oct 10.	10.1021/acs.analchem.4c03274	https://doi.org/10.1021/acs.analchem.4c03274
Guttman	35716664	2022	Reiter KH	Cullin-independent recognition of HHARI substrates by a dynamic RBR catalytic domain	Structure. 2022 Sep 1;30(9):1269-1284.e6. doi: 10.1016/j.str.2022.05.017. Epub 2022 Jun 17.	10.1016/j.str.2022.05.017	https://doi.org/10.1016/j.str.2022.05.017
Guttman	37121546	2023	Garcia NK	Structural dynamics reveal subtype-specific activation and inhibition of influenza virus hemagglutinin	J Biol Chem. 2023 Jun;299(6):104765. doi: 10.1016/j.jbc.2023.104765. Epub 2023 Apr 28.	10.1016/j.jbc.2023.104765	https://doi.org/10.1016/j.jbc.2023.104765
Guttman	35938988	2022	Hale M	IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2	J Exp Med. 2022 Sep 5;219(9):e20220849. doi: 10.1084/jem.20220849. Epub 2022 Aug 8.	10.1084/jem.20220849	https://doi.org/10.1084/jem.20220849
Guttman	38352474	2024	James EI	Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation	bioRxiv [Preprint]. 2024 Feb 3:2024.02.02.578649. doi: 10.1101/2024.02.02.578649.	10.1101/2024.02.02.578649	https://doi.org/10.1101/2024.02.02.578649
Guttman	38096052	2023	Dosey A	Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses	Cell Rep. 2023 Dec 26;42(12):113553. doi: 10.1016/j.celrep.2023.113553. Epub 2023 Dec 13.	10.1016/j.celrep.2023.113553	https://doi.org/10.1016/j.celrep.2023.113553
Guttman	40161831	2025	Tuttle LM	A framework for automated multimodal HDX-MS analysis	bioRxiv [Preprint]. 2025 Mar 15:2025.03.13.643099. doi: 10.1101/2025.03.13.643099.	10.1101/2025.03.13.643099	https://doi.org/10.1101/2025.03.13.643099
Guttman	41067539	2025	Mundorff CC	Mapping Hydrogen Migration Thresholds for Site-Specific HDX-MS	Mol Cell Proteomics. 2025 Nov;24(11):101075. doi: 10.1016/j.mcpro.2025.101075. Epub 2025 Oct 9.	10.1016/j.mcpro.2025.101075	https://doi.org/10.1016/j.mcpro.2025.101075
Guttman	32933460	2020	Alonge KM	Rapid Differentiation of Chondroitin Sulfate Isomers by Gas-phase Hydrogen-deuterium Exchange	Curr Mol Med. 2020;20(10):821-827. doi: 10.2174/1566524020666200915110707.	10.2174/1566524020666200915110707	https://doi.org/10.2174/1566524020666200915110707
Guttman	39950825	2025	Vance DJ	A type-specific B-cell epitope at the apex of outer surface protein C (OspC) of the Lyme disease spirochete, Borreliella burgdorferi	Microbiol Spectr. 2025 Apr;13(4):e0288324. doi: 10.1128/spectrum.02883-24. Epub 2025 Feb 14.	10.1128/spectrum.02883-24	https://doi.org/10.1128/spectrum.02883-24
Guttman	37292967	2023	Dosey A	Combinatorial immune refocusing within the influenza hemagglutinin head elicits cross-neutralizing antibody responses	bioRxiv [Preprint]. 2023 May 24:2023.05.23.541996. doi: 10.1101/2023.05.23.541996.	10.1101/2023.05.23.541996	https://doi.org/10.1101/2023.05.23.541996
Guttman	40692775	2025	Rudolph MJ	Germline encoded residues dominate the interaction of a human monoclonal antibody with decorin binding protein A of Borrelia burgdorferi	Front Immunol. 2025 Jul 7;16:1611828. doi: 10.3389/fimmu.2025.1611828. eCollection 2025.	10.3389/fimmu.2025.1611828	https://doi.org/10.3389/fimmu.2025.1611828
Guttman	41140027	2025	Murphree T	Comprehensive Internal Standards for Hydrogen-Deuterium Exchange Mass Spectrometry	Anal Chem. 2025 Nov 4;97(43):24217-24224. doi: 10.1021/acs.analchem.5c05191. Epub 2025 Oct 27.	10.1021/acs.analchem.5c05191	https://doi.org/10.1021/acs.analchem.5c05191
Guttman	36036783	2022	Hale M	Correction: IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2	J Exp Med. 2022 Sep 5;219(9):jem.2022084908172022c. doi: 10.1084/jem.2022084908172022c. Epub 2022 Aug 29.	10.1084/jem.2022084908172022c	https://doi.org/10.1084/jem.2022084908172022c
Guttman	32368904	2020	Uppal SS	High-Precision, Gas-Phase Hydrogen/Deuterium-Exchange Kinetics by Mass Spectrometry Enabled by Exchange Standards	Anal Chem. 2020 Jun 2;92(11):7725-7732. doi: 10.1021/acs.analchem.0c00749. Epub 2020 May 18.	10.1021/acs.analchem.0c00749	https://doi.org/10.1021/acs.analchem.0c00749
Guttman	32569457	2020	Murphree TA	Imidazolium Compounds as Internal Exchange Reporters for Hydrogen/Deuterium Exchange by Mass Spectrometry	Anal Chem. 2020 Jul 21;92(14):9830-9837. doi: 10.1021/acs.analchem.0c01328. Epub 2020 Jul 7.	10.1021/acs.analchem.0c01328	https://doi.org/10.1021/acs.analchem.0c01328
Guttman	41279711	2025	James EI	Tau4RD fibril polymorphism is imprinted during early aggregation	bioRxiv [Preprint]. 2025 Oct 14:2025.10.12.681486. doi: 10.1101/2025.10.12.681486.	10.1101/2025.10.12.681486	https://doi.org/10.1101/2025.10.12.681486
Guttman	33284630	2021	Watson MJ	Simple Platform for Automating Decoupled LC-MS Analysis of Hydrogen/Deuterium Exchange Samples	J Am Soc Mass Spectrom. 2021 Feb 3;32(2):597-600. doi: 10.1021/jasms.0c00341. Epub 2020 Dec 7.	10.1021/jasms.0c00341	https://doi.org/10.1021/jasms.0c00341
Guttman	39078213	2024	Janowska MK	HDXBoxeR: an R package for statistical analysis and visualization of multiple Hydrogen-Deuterium Exchange Mass-Spectrometry datasets of different protein states	Bioinformatics. 2024 Aug 2;40(8):btae479. doi: 10.1093/bioinformatics/btae479.	10.1093/bioinformatics/btae479	https://doi.org/10.1093/bioinformatics/btae479
Guttman	38782973	2024	Francis KL	Characterizing the human intestinal chondroitin sulfate glycosaminoglycan sulfation signature in inflammatory bowel disease	Sci Rep. 2024 May 23;14(1):11839. doi: 10.1038/s41598-024-60959-x.	10.1038/s41598-024-60959-x	https://doi.org/10.1038/s41598-024-60959-x
Guttman	32868832	2020	Guttman M	The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8	Sci Rep. 2020 Aug 31;10(1):14313. doi: 10.1038/s41598-020-71184-7.	10.1038/s41598-020-71184-7	https://doi.org/10.1038/s41598-020-71184-7
Guttman	37683649	2024	Chakraborty S	Profiling of drug resistance in Src kinase at scale uncovers a regulatory network coupling autoinhibition and catalytic domain dynamics	Cell Chem Biol. 2024 Feb 15;31(2):207-220.e11. doi: 10.1016/j.chembiol.2023.08.005. Epub 2023 Sep 7.	10.1016/j.chembiol.2023.08.005	https://doi.org/10.1016/j.chembiol.2023.08.005
Guttman	32817941	2020	Walls AC	Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2	bioRxiv [Preprint]. 2020 Aug 12:2020.08.11.247395. doi: 10.1101/2020.08.11.247395.	10.1101/2020.08.11.247395	https://doi.org/10.1101/2020.08.11.247395
Guttman	39240158	2024	Rudolph MJ	Structure of a Human Monoclonal Antibody in Complex with Outer Surface Protein C of the Lyme Disease Spirochete, Borreliella burgdorferi	J Immunol. 2024 Oct 15;213(8):1234-1243. doi: 10.4049/jimmunol.2400247.	10.4049/jimmunol.2400247	https://doi.org/10.4049/jimmunol.2400247
Guttman	38746285	2024	Rudolph MJ	Structure of a human monoclonal antibody in complex with Outer surface protein C (OspC) of the Lyme disease spirochete, Borreliella burgdorferi	bioRxiv [Preprint]. 2024 May 3:2024.04.29.591597. doi: 10.1101/2024.04.29.591597.	10.1101/2024.04.29.591597	https://doi.org/10.1101/2024.04.29.591597
Guttman	32808771	2020	Silzel JW	Probing the Stability of Proline Cis/Trans Isomers in the Gas Phase with Ultraviolet Photodissociation	J Am Soc Mass Spectrom. 2020 Sep 2;31(9):1974-1980. doi: 10.1021/jasms.0c00242. Epub 2020 Aug 18.	10.1021/jasms.0c00242	https://doi.org/10.1021/jasms.0c00242
Guttman	33984240	2021	Vorauer C	Rapid Assessment of Pepsin Column Activity for Reliable HDX-MS Studies	J Am Soc Mass Spectrom. 2021 Sep 1;32(9):2386-2390. doi: 10.1021/jasms.1c00080. Epub 2021 May 13.	10.1021/jasms.1c00080	https://doi.org/10.1021/jasms.1c00080
Guttman	32895577	2020	Alonge KM	Hypothalamic perineuronal net assembly is required for sustained diabetes remission induced by fibroblast growth factor 1 in rats	Nat Metab. 2020 Oct;2(10):1025-1033. doi: 10.1038/s42255-020-00275-6. Epub 2020 Sep 7.	10.1038/s42255-020-00275-6	https://doi.org/10.1038/s42255-020-00275-6
Guttman	41278827	2025	Stone NL	Disorder with consequence: Phosphorylation sites in HSPB5 yield distinct structural outcomes	bioRxiv [Preprint]. 2025 Oct 28:2025.10.27.684587. doi: 10.1101/2025.10.27.684587.	10.1101/2025.10.27.684587	https://doi.org/10.1101/2025.10.27.684587
Guttman	39788320	2025	Moroco JA	High-Throughput Determination of Exchange Rates of Unmodified and PTM-Containing Peptides Using HX-MS	Mol Cell Proteomics. 2025 Feb;24(2):100904. doi: 10.1016/j.mcpro.2025.100904. Epub 2025 Jan 7.	10.1016/j.mcpro.2025.100904	https://doi.org/10.1016/j.mcpro.2025.100904
Lee	41542432	2026	Croft JT	Structure of HIV-1 Env glycoprotein on virions reveals an alternative fusion subunit organization and native membrane coupling	Croft JT, Do HN, Leaman DP, Lovendahl KN, Ralli-Jain P, Chase KJ, Chen C, Prasad VM, Derdeyn CA, Zwick MB, Gnanakaran S, Lee KK. Structure of HIV-1 Env glycoprotein on virions reveals an alternative fusion subunit organization and native membrane coupling. bioRxiv [Preprint]. 2026 Jan 10:2026.01.09.698652. doi: 10.64898/2026.01.09.698652. PMID: 41542432; PMCID: PMC12803169.	10.64898/2026.01.09.698652	https://doi.org/10.64898/2026.01.09.698652
Lee	41648420	2026	Croft JT	Reconstructing a Missing Link of HIV-1 Assembly: HIV-1 Envelope-Matrix Interactions in a Native Viral Context	Croft JT, Do HN, Leaman DP, Lovendahl KN, Ralli-Jain P, Chase KJ, Derdeyn CA, Zwick MB, Gnanakaran S, Lee KK. Reconstructing a Missing Link of HIV-1 Assembly: HIV-1 Envelope-Matrix Interactions in a Native Viral Context. bioRxiv [Preprint]. 2026 Jan 16:2026.01.15.699503. doi: 10.64898/2026.01.15.699503. PMID: 41648420; PMCID: PMC12871272.	10.64898/2026.01.15.699503	https://doi.org/10.64898/2026.01.15.699503
Lee	33762730	2021	Boyoglu-Barnum S	Quadrivalent influenza nanoparticle vaccines induce broad protection	Nature. 2021 Apr;592(7855):623-628. doi: 10.1038/s41586-021-03365-x. Epub 2021 Mar 24.	10.1038/s41586-021-03365-x	https://doi.org/10.1038/s41586-021-03365-x
Lee	33160446	2020	Walls AC	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2	Cell. 2020 Nov 25;183(5):1367-1382.e17. doi: 10.1016/j.cell.2020.10.043. Epub 2020 Oct 31.	10.1016/j.cell.2020.10.043	https://doi.org/10.1016/j.cell.2020.10.043
Lee	39054240	2024	Kephart SM	Visualizing intermediate stages of viral membrane fusion by cryo-electron tomography	Trends Biochem Sci. 2024 Oct;49(10):916-931. doi: 10.1016/j.tibs.2024.06.012. Epub 2024 Jul 24.	10.1016/j.tibs.2024.06.012	https://doi.org/10.1016/j.tibs.2024.06.012
Lee	31721348	2020	Hodge EA	Bridging protein structure, dynamics, and function using hydrogen/deuterium-exchange mass spectrometry	Protein Sci. 2020 Apr;29(4):843-855. doi: 10.1002/pro.3790. Epub 2019 Nov 25.	10.1002/pro.3790	https://doi.org/10.1002/pro.3790
Lee	36244308	2022	Yip JA	Emotions and ethics: How emotions sensitize perceptions of the consequences for self and others to motivate unethical behavior	Curr Opin Psychol. 2022 Dec;48:101464. doi: 10.1016/j.copsyc.2022.101464. Epub 2022 Sep 7.	10.1016/j.copsyc.2022.101464	https://doi.org/10.1016/j.copsyc.2022.101464
Lee	35383176	2022	Ellis D	Structure-based design of stabilized recombinant influenza neuraminidase tetramers	Nat Commun. 2022 Apr 5;13(1):1825. doi: 10.1038/s41467-022-29416-z.	10.1038/s41467-022-29416-z	https://doi.org/10.1038/s41467-022-29416-z
Lee	41350454	2025	Kephart SM	Host switching mutations in H5N1 influenza hemagglutinin suppress site-specific activation dynamics	Nat Commun. 2025 Dec 5;17(1):234. doi: 10.1038/s41467-025-66926-y.	10.1038/s41467-025-66926-y	https://doi.org/10.1038/s41467-025-66926-y
Lee	37632837	2023	Goldbach N	De novo design of monomeric helical bundles for pH-controlled membrane lysis	Protein Sci. 2023 Nov;32(11):e4769. doi: 10.1002/pro.4769.	10.1002/pro.4769	https://doi.org/10.1002/pro.4769
Lee	32276357	2020	Benhaim MA	New Biophysical Approaches Reveal the Dynamics and Mechanics of Type I Viral Fusion Machinery and Their Interplay with Membranes	Viruses. 2020 Apr 8;12(4):413. doi: 10.3390/v12040413.	10.3390/v12040413	https://doi.org/10.3390/v12040413
Lee	38626690	2024	Yip JA	Comedy, consensus, and conflict framework: Comedy as a norm violation can build consensus or escalate conflict in negotiations	Curr Opin Psychol. 2024 Jun;57:101814. doi: 10.1016/j.copsyc.2024.101814. Epub 2024 Mar 26.	10.1016/j.copsyc.2024.101814	https://doi.org/10.1016/j.copsyc.2024.101814	I don't think this is Kelly
Lee	37121546	2023	Garcia NK	Structural dynamics reveal subtype-specific activation and inhibition of influenza virus hemagglutinin	J Biol Chem. 2023 Jun;299(6):104765. doi: 10.1016/j.jbc.2023.104765. Epub 2023 Apr 28.	10.1016/j.jbc.2023.104765	https://doi.org/10.1016/j.jbc.2023.104765
Lee	37166130	2023	Chen C	hACE2-Induced Allosteric Activation in SARS-CoV versus SARS-CoV-2 Spike Assemblies Revealed by Structural Dynamics	ACS Infect Dis. 2023 Jun 9;9(6):1180-1189. doi: 10.1021/acsinfecdis.3c00010. Epub 2023 May 11.	10.1021/acsinfecdis.3c00010	https://doi.org/10.1021/acsinfecdis.3c00010
Lee	38129390	2023	Roier S	mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents	NPJ Vaccines. 2023 Dec 22;8(1):190. doi: 10.1038/s41541-023-00790-z.	10.1038/s41541-023-00790-z	https://doi.org/10.1038/s41541-023-00790-z
Lee	36790205	2023	Zhang L	Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions	J Virol. 2023 Mar 30;97(3):e0165022. doi: 10.1128/jvi.01650-22. Epub 2023 Feb 15.	10.1128/jvi.01650-22	https://doi.org/10.1128/jvi.01650-22
Lee	38096052	2023	Dosey A	Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses	Cell Rep. 2023 Dec 26;42(12):113553. doi: 10.1016/j.celrep.2023.113553. Epub 2023 Dec 13.	10.1016/j.celrep.2023.113553	https://doi.org/10.1016/j.celrep.2023.113553
Lee	35977542	2022	McLeod B	Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses	Immunity. 2022 Sep 13;55(9):1680-1692.e8. doi: 10.1016/j.immuni.2022.07.015. Epub 2022 Aug 16.	10.1016/j.immuni.2022.07.015	https://doi.org/10.1016/j.immuni.2022.07.015
Lee	35021101	2022	Read BJ	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens	Cell Rep. 2022 Jan 11;38(2):110217. doi: 10.1016/j.celrep.2021.110217.	10.1016/j.celrep.2021.110217	https://doi.org/10.1016/j.celrep.2021.110217
Lee	35677643	2022	Hodge EA	Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env	iScience. 2022 May 23;25(6):104449. doi: 10.1016/j.isci.2022.104449. eCollection 2022 Jun 17.	10.1016/j.isci.2022.104449	https://doi.org/10.1016/j.isci.2022.104449
Lee	35970990	2022	Mangala Prasad V	Visualization of conformational changes and membrane remodeling leading to genome delivery by viral class-II fusion machinery	Nat Commun. 2022 Aug 15;13(1):4772. doi: 10.1038/s41467-022-32431-9.	10.1038/s41467-022-32431-9	https://doi.org/10.1038/s41467-022-32431-9
Lee	35123651	2022	Mangala Prasad V	Cryo-ET of Env on intact HIV virions reveals structural variation and positioning on the Gag lattice	Cell. 2022 Feb 17;185(4):641-653.e17. doi: 10.1016/j.cell.2022.01.013. Epub 2022 Feb 4.	10.1016/j.cell.2022.01.013	https://doi.org/10.1016/j.cell.2022.01.013
Lee	37292967	2023	Dosey A	Combinatorial immune refocusing within the influenza hemagglutinin head elicits cross-neutralizing antibody responses	bioRxiv [Preprint]. 2023 May 24:2023.05.23.541996. doi: 10.1101/2023.05.23.541996.	10.1101/2023.05.23.541996	https://doi.org/10.1101/2023.05.23.541996
Lee	33427196	2021	Doepker LE	Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies	Elife. 2021 Jan 11;10:e63444. doi: 10.7554/eLife.63444.	10.7554/eLife.63444	https://doi.org/10.7554/elife.63444
Lee	37253011	2023	Guenthoer J	Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection	Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2220948120. doi: 10.1073/pnas.2220948120. Epub 2023 May 30.	10.1073/pnas.2220948120	https://doi.org/10.1073/pnas.2220948120
Lee	32759217	2020	Cornell CE	Direct imaging of liquid domains in membranes by cryo-electron tomography	Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19713-19719. doi: 10.1073/pnas.2002245117. Epub 2020 Aug 5.	10.1073/pnas.2002245117	https://doi.org/10.1073/pnas.2002245117
Lee	40371173	2025	Lee KK	Unleashing virus structural biology: Probing protein and membrane intermediates in the dynamic process of membrane fusion	QRB Discov. 2025 Mar 31;6:e14. doi: 10.1017/qrd.2025.3. eCollection 2025.	10.1017/qrd.2025.3	https://doi.org/10.1017/qrd.2025.3
Lee	34856127	2021	Lee KK	How a broadly neutralizing antibody grapples with antigenic and conformational diversity in dengue virus	Cell. 2021 Dec 9;184(25):6015-6016. doi: 10.1016/j.cell.2021.11.020. Epub 2021 Dec 1.	10.1016/j.cell.2021.11.020	https://doi.org/10.1016/j.cell.2021.11.020
Lee	35235790	2022	Sahoo A	Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies	Cell Rep. 2022 Mar 1;38(9):110436. doi: 10.1016/j.celrep.2022.110436.	10.1016/j.celrep.2022.110436	https://doi.org/10.1016/j.celrep.2022.110436
Lee	38665238	2023	Hodge EA	An HIV-1 broadly neutralizing antibody overcomes structural and dynamic variation through highly focused epitope targeting	Npj Viruses. 2023;1(1):2. doi: 10.1038/s44298-023-00002-4. Epub 2023 Oct 5.	10.1038/s44298-023-00002-4	https://doi.org/10.1038/s44298-023-00002-4
Lee	41279711	2025	James EI	Tau4RD fibril polymorphism is imprinted during early aggregation	bioRxiv [Preprint]. 2025 Oct 14:2025.10.12.681486. doi: 10.1101/2025.10.12.681486.	10.1101/2025.10.12.681486	https://doi.org/10.1101/2025.10.12.681486
Lee	33284630	2021	Watson MJ	Simple Platform for Automating Decoupled LC-MS Analysis of Hydrogen/Deuterium Exchange Samples	J Am Soc Mass Spectrom. 2021 Feb 3;32(2):597-600. doi: 10.1021/jasms.0c00341. Epub 2020 Dec 7.	10.1021/jasms.0c00341	https://doi.org/10.1021/jasms.0c00341
Lee	34263727	2021	Shipley MM	Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection	Elife. 2021 Jul 15;10:e68110. doi: 10.7554/eLife.68110.	10.7554/eLife.68110	https://doi.org/10.7554/elife.68110
Lee	32868832	2020	Guttman M	The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8	Sci Rep. 2020 Aug 31;10(1):14313. doi: 10.1038/s41598-020-71184-7.	10.1038/s41598-020-71184-7	https://doi.org/10.1038/s41598-020-71184-7
Lee	36561191	2023	Guenthoer J	Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection	bioRxiv [Preprint]. 2023 Mar 29:2022.12.15.520606. doi: 10.1101/2022.12.15.520606.	10.1101/2022.12.15.520606	https://doi.org/10.1101/2022.12.15.520606
Lee	34267764	2021	Ellis D	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design	Front Immunol. 2021 Jun 29;12:710263. doi: 10.3389/fimmu.2021.710263. eCollection 2021.	10.3389/fimmu.2021.710263	https://doi.org/10.3389/fimmu.2021.710263
Lee	32817941	2020	Walls AC	Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2	bioRxiv [Preprint]. 2020 Aug 12:2020.08.11.247395. doi: 10.1101/2020.08.11.247395.	10.1101/2020.08.11.247395	https://doi.org/10.1101/2020.08.11.247395
Lee	34559844	2021	Aljedani SS	Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization	PLoS Pathog. 2021 Sep 24;17(9):e1009543. doi: 10.1371/journal.ppat.1009543. eCollection 2021 Sep.	10.1371/journal.ppat.1009543	https://doi.org/10.1371/journal.ppat.1009543
Lee	41279505	2025	Kephart SM	Host Switching Mutations in H5N1 Influenza Hemagglutinin Suppress Site-specific Activation Dynamics	bioRxiv [Preprint]. 2025 Oct 6:2025.10.06.680362. doi: 10.1101/2025.10.06.680362.	10.1101/2025.10.06.680362	https://doi.org/10.1101/2025.10.06.680362
Lee	40982561	2025	Chen C	Interprotomer crosstalk in mosaic viral glycoprotein trimers provides insight into polyvalent immunogen co-assembly	PLoS Pathog. 2025 Sep 22;21(9):e1013143. doi: 10.1371/journal.ppat.1013143. eCollection 2025 Sep.	10.1371/journal.ppat.1013143	https://doi.org/10.1371/journal.ppat.1013143
Rettie	41761900	2026	Raj PS	Safety Assessment of Salvia officinalis (Sage)-Derived Ingredients as Used in Cosmetics	Raj PS, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Peterson LA, Rettie AE, Ross D, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume MM, Heldreth B. Safety Assessment of Salvia officinalis (Sage)-Derived Ingredients as Used in Cosmetics. Int J Toxicol. 2026 Feb;45(1_suppl):88S-105S. doi: 10.1177/10915818261425569. Epub 2026 Feb 28.	10.1177/10915818261425569	https://doi.org/10.1177/10915818261425569	4/28/26
Rettie	41761875	2026	Ferguson P	Safety Assessment of Zingiber officinale (Ginger) - Derived Ingredients as Used in Cosmetics	Ferguson P, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Rettie AE, Ross D, Liebler DC, Peterson LA, Rettie AE, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume MM, Heldreth B. Safety Assessment of Zingiber officinale (Ginger) - Derived Ingredients as Used in Cosmetics. Int J Toxicol. 2026 Feb;45(1_suppl):5S-26S. doi: 10.1177/10915818261425573. Epub 2026 Feb 28. PMID: 41761875.	10.1177/10915818261425573	https://doi.org/10.1177/10915818261425573	4/28/26
Rettie	41761848	2026	Johnson W Jr	Safety Assessment of Starch Phosphates as Used in Cosmetics	Johnson W Jr, Tucker R, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Rettie AE, Ross D, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume M, Heldreth B. Safety Assessment of Starch Phosphates as Used in Cosmetics. Int J Toxicol. 2026 Feb;45(1_suppl):48S-67S. doi: 10.1177/10915818261425590. Epub 2026 Feb 28.	10.1177/10915818261425590	https://doi.org/10.1177/10915818261425590	4/28/26
Rettie	41761683	2026	Burnett CL	Safety Assessment of Barley-Derived Ingredients as Used in Cosmetics	Burnett CL, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Peterson LA, Rettie AE, Ross D, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume MM, Heldreth B. Safety Assessment of Barley-Derived Ingredients as Used in Cosmetics. Int J Toxicol. 2026 Feb;45(1_suppl):68S-87S. doi: 10.1177/10915818261425577. Epub 2026 Feb 27.	10.1177/10915818261425577	https://doi.org/10.1177/10915818261425577	4/28/26
Rettie	41757447	2026	Ferguson P	Safety Assessment of Glucosamine Ingredients as Used in Cosmetics	Ferguson P, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Rettie AE, Ross D, Peterson LA, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume MM, Heldreth B. Safety Assessment of Glucosamine Ingredients as Used in Cosmetics. Int J Toxicol. 2026 Feb;45(1_suppl):27S-47S. doi: 10.1177/10915818261425571. Epub 2026 Feb 27.	10.1177/10915818261425571	https://doi.org/10.1177/10915818261425571	4/28/26
Rettie	41693072	2026	Raj PS	Safety Assessment of Fatty Ethers as Used in Cosmetics	Raj PS, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Rettie AE, Ross D, Liebler DC, Peterson LA, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume MM, Heldreth B. Safety Assessment of Fatty Ethers as Used in Cosmetics. Int J Toxicol. 2026 Feb;45(1_suppl):122S-135S. doi: 10.1177/10915818261425572. Epub 2026 Feb 15.	10.1177/10915818261425572	https://doi.org/10.1177/10915818261425572	4/28/26
Rettie	41566662	2026	Cheng S	A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs	Cheng S, Flora DR, Jaber MM, Rettie AE, Brundage RC, Tracy TS. A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs. Br J Pharmacol. 2026 May;183(10):2482-2496. doi: 10.1111/bph.70337. Epub 2026 Jan 21.	10.1111/bph.70337	https://doi.org/10.1111/bph.70337	4/28/26
Rettie	31801692	2020	Thesseling FA	Novel insights into oxidation of fatty acids and fatty alcohols by cytochrome P450 monooxygenase CYP4B1	Arch Biochem Biophys. 2020 Jan 15;679:108216. doi: 10.1016/j.abb.2019.108216. Epub 2019 Dec 1.	10.1016/j.abb.2019.108216	https://doi.org/10.1016/j.abb.2019.108216
Rettie	32423989	2020	McDonald MG	Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People	J Pharmacol Exp Ther. 2020 Aug;374(2):233-240. doi: 10.1124/jpet.120.265850. Epub 2020 May 18.	10.1124/jpet.120.265850	https://doi.org/10.1124/jpet.120.265850
Rettie	34314704	2021	Amorosi CJ	Massively parallel characterization of CYP2C9 variant enzyme activity and abundance	Am J Hum Genet. 2021 Sep 2;108(9):1735-1751. doi: 10.1016/j.ajhg.2021.07.001. Epub 2021 Jul 26.	10.1016/j.ajhg.2021.07.001	https://doi.org/10.1016/j.ajhg.2021.07.001
Rettie	36768362	2023	RÃÂÃÂ¶der A	Spotlight on CYP4B1	Int J Mol Sci. 2023 Jan 20;24(3):2038. doi: 10.3390/ijms24032038.	10.3390/ijms24032038	https://doi.org/10.3390/ijms24032038
Rettie	32216088	2020	Fohner AE	Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions	Clin Transl Sci. 2020 Sep;13(5):1004-1009. doi: 10.1111/cts.12787. Epub 2020 Apr 18.	10.1111/cts.12787	https://doi.org/10.1111/cts.12787
Rettie	32302132	2020	Kowalski JP	Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1	J Med Chem. 2020 May 14;63(9):4824-4836. doi: 10.1021/acs.jmedchem.0c00101. Epub 2020 Apr 30.	10.1021/acs.jmedchem.0c00101	https://doi.org/10.1021/acs.jmedchem.0c00101
Rettie	32779747	2021	Karnes JH	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update	Clin Pharmacol Ther. 2021 Feb;109(2):302-309. doi: 10.1002/cpt.2008. Epub 2020 Sep 6.	10.1002/cpt.2008	https://doi.org/10.1002/cpt.2008
Rettie	34699676	2022	Cox EJ	Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach	Clin Transl Sci. 2022 Feb;15(2):322-329. doi: 10.1111/cts.13172. Epub 2021 Oct 26.	10.1111/cts.13172	https://doi.org/10.1111/cts.13172
Rettie	32004415	2020	Basit A	A Novel LC-MS/MS Assay for Quantification of Des-carboxy Prothrombin and Characterization of Warfarin-Induced Changes	Clin Transl Sci. 2020 Jul;13(4):718-726. doi: 10.1111/cts.12757. Epub 2020 Mar 9.	10.1111/cts.12757	https://doi.org/10.1111/cts.12757
Rettie	32905824	2020	Imaoka T	Microphysiological system modeling of ochratoxin A-associated nephrotoxicity	Toxicology. 2020 Nov;444:152582. doi: 10.1016/j.tox.2020.152582. Epub 2020 Sep 6.	10.1016/j.tox.2020.152582	https://doi.org/10.1016/j.tox.2020.152582
Rettie	33632714	2021	Henderson LM	In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup'ik Alaska Native Population	Drug Metab Dispos. 2021 May;49(5):345-352. doi: 10.1124/dmd.120.000301. Epub 2021 Feb 25.	10.1124/dmd.120.000301	https://doi.org/10.1124/dmd.120.000301
Rettie	33993844	2021	Kowalski JP	Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H- benzotriazol-1-yl)amino]octanoic acid, a selective inhibitor of human cytochrome P450 4Z1: ÃÂÃÂ²-oxidation as a potential augmenting pathway for inhibition	Xenobiotica. 2021 Aug;51(8):901-915. doi: 10.1080/00498254.2021.1930281. Epub 2021 Jun 11.	10.1080/00498254.2021.1930281	https://doi.org/10.1080/00498254.2021.1930281
Rettie	31536170	2020	Dalton R	Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity	Clin Transl Sci. 2020 Jan;13(1):147-156. doi: 10.1111/cts.12695. Epub 2019 Oct 25.	10.1111/cts.12695	https://doi.org/10.1111/cts.12695
Rettie	32591416	2020	McDonald MG	Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects	Drug Metab Dispos. 2020 Oct;48(10):1018-1027. doi: 10.1124/dmd.120.091041. Epub 2020 Jun 26.	10.1124/dmd.120.091041	https://doi.org/10.1124/dmd.120.091041
Rettie	32870157	2020	Chiasson MA	Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact	Elife. 2020 Sep 1;9:e58026. doi: 10.7554/eLife.58026.	10.7554/eLife.58026	https://doi.org/10.7554/elife.58026
Rettie	33093187	2021	Tanna RS	Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations	J Pharmacol Exp Ther. 2021 Jan;376(1):64-73. doi: 10.1124/jpet.120.000270. Epub 2020 Oct 22.	10.1124/jpet.120.000270	https://doi.org/10.1124/jpet.120.000270
Rettie	33712517	2021	Cox EJ	Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach	Pharmacol Rev. 2021 Apr;73(2):847-859. doi: 10.1124/pharmrev.120.000106.	10.1124/pharmrev.120.000106	https://doi.org/10.1124/pharmrev.120.000106
Rettie	35335999	2022	Tanna RS	Clinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants	Pharmaceutics. 2022 Mar 11;14(3):620. doi: 10.3390/pharmaceutics14030620.	10.3390/pharmaceutics14030620	https://doi.org/10.3390/pharmaceutics14030620
Rettie	35798368	2022	Cheng S	Pharmacokinetic Modeling of Warfarin ÃÂÃÂI - Model-based Analysis of Warfarin Metabolites following Warfarin Administered either Alone or Together with Fluconazole or Rifampin	Drug Metab Dispos. 2022 Jul 7;50(9):1302-11. doi: 10.1124/dmd.122.000877.	10.1124/dmd.122.000877	https://doi.org/10.1124/dmd.122.000877
Rettie	35798369	2022	Cheng S	Pharmacokinetic Modeling of Warfarin ÃÂÃÂ - Model-based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-dependent Drug-drug Interactions of S-Warfarin	Drug Metab Dispos. 2022 Jul 7;50(9):1287-301. doi: 10.1124/dmd.122.000876.	10.1124/dmd.122.000876	https://doi.org/10.1124/dmd.122.000876
Rettie	36379708	2023	Cheng S	A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various CYP2C9 Genotypes under Different Cotreatments	Drug Metab Dispos. 2023 Feb;51(2):257-267. doi: 10.1124/dmd.122.001048. Epub 2022 Nov 15.	10.1124/dmd.122.001048	https://doi.org/10.1124/dmd.122.001048
Rettie	36924284	2023	Tanna RS	Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom	Clin Pharmacol Ther. 2023 Jun;113(6):1315-1325. doi: 10.1002/cpt.2891. Epub 2023 Mar 28.	10.1002/cpt.2891	https://doi.org/10.1002/cpt.2891
Rettie	40932363	2025	Fiume MM	Re-Review Summary of Ricinus Communis (Castor) Seed Oil and Ricinoleates as Used in Cosmetics	Int J Toxicol. 2025 Oct;44(3_suppl):117S-122S. doi: 10.1177/10915818251361102. Epub 2025 Sep 11.	10.1177/10915818251361102	https://doi.org/10.1177/10915818251361102
Rettie	40932360	2025	Raj P	Re-Review Summary of Cholesterol as Used in Cosmetics	Int J Toxicol. 2025 Oct;44(3_suppl):129S-132S. doi: 10.1177/10915818251359226. Epub 2025 Sep 11.	10.1177/10915818251359226	https://doi.org/10.1177/10915818251359226
Rettie	40932357	2025	Raj PS	Re-Review Summary of VA/Crotonates Copolymer as Used in Cosmetics	Int J Toxicol. 2025 Oct;44(3_suppl):133S-135S. doi: 10.1177/10915818251359221. Epub 2025 Sep 11.	10.1177/10915818251359221	https://doi.org/10.1177/10915818251359221
Rettie	40932355	2025	Fiume MM	Re-Review Summary of PEG Stearates as Used in Cosmetics	Int J Toxicol. 2025 Oct;44(3_suppl):100S-116S. doi: 10.1177/10915818251359230. Epub 2025 Sep 11.	10.1177/10915818251359230	https://doi.org/10.1177/10915818251359230
Rettie	40932353	2025	Fiume MM	Re-Review Summary of Sodium Sesquicarbonate, Sodium Carbonate, and Sodium Bicarbonate as Used in Cosmetics	Int J Toxicol. 2025 Oct;44(3_suppl):123S-128S. doi: 10.1177/10915818251361098. Epub 2025 Sep 11.	10.1177/10915818251361098	https://doi.org/10.1177/10915818251361098
Rettie	40577420	2025	HÃÂÃÂ¼sken S	Functional analysis of CYP4B1 enzymes from apes and humans uncovers evolutionary hot spots for adaptations of the catalytical function	PLoS Genet. 2025 Jun 27;21(6):e1011750. doi: 10.1371/journal.pgen.1011750. eCollection 2025 Jun.	10.1371/journal.pgen.1011750	https://doi.org/10.1371/journal.pgen.1011750
Rettie	39319420	2024	Boyle GE	Deep mutational scanning of CYP2C19 in human cells reveals a substrate specificity-abundance tradeoff	Genetics. 2024 Nov 6;228(3):iyae156. doi: 10.1093/genetics/iyae156.	10.1093/genetics/iyae156	https://doi.org/10.1093/genetics/iyae156
Rettie	38913451	2024	Cherian P	Sodium Dehydroacetate and Dehydroacetic Acid	Int J Toxicol. 2024 Oct;43(4_suppl):130-134. doi: 10.1177/10915818241260276. Epub 2024 Jun 24.	10.1177/10915818241260276	https://doi.org/10.1177/10915818241260276
Rettie	38872413	2025	Tucker R	Isobutane, Isopentane, Butane, and Propane	Int J Toxicol. 2025 Feb;44(1_suppl):17S-21S. doi: 10.1177/10915818241260280. Epub 2024 Jun 14.	10.1177/10915818241260280	https://doi.org/10.1177/10915818241260280
Rettie	38604728	2024	Kowalski JP	There and Back Again: A Perspective on 20 Years of CYP4Z1	Drug Metab Dispos. 2024 May 16;52(6):498-507. doi: 10.1124/dmd.124.001670.	10.1124/dmd.124.001670	https://doi.org/10.1124/dmd.124.001670
Rettie	38481683	2024	Alade AN	Cytochrome P450 Family 4F2 and 4F11 Haplotype Mapping and Association with Hepatic Gene Expression and Vitamin K Hydroxylation Activity	ACS Pharmacol Transl Sci. 2024 Feb 3;7(3):716-732. doi: 10.1021/acsptsci.3c00287. eCollection 2024 Mar 8.	10.1021/acsptsci.3c00287	https://doi.org/10.1021/acsptsci.3c00287
Rettie	37996163	2023	Singh DK	Characterization of Gla proteoforms and non-Gla peptides of gamma carboxylated proteins: Application to quantification of prothrombin proteoforms in human plasma	Anal Chim Acta. 2023 Dec 15;1284:341972. doi: 10.1016/j.aca.2023.341972. Epub 2023 Nov 5.	10.1016/j.aca.2023.341972	https://doi.org/10.1016/j.aca.2023.341972
Rettie	37956555	2023	Pelletier RD	Improved methods for the detection of heme and protoporphyrin IX adducts and quantification of heme B from cytochrome P450 containing systems	J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Dec 1;1231:123921. doi: 10.1016/j.jchromb.2023.123921. Epub 2023 Nov 10.	10.1016/j.jchromb.2023.123921	https://doi.org/10.1016/j.jchromb.2023.123921
Rettie	37885364	2023	Urbaniak A	Experimental pharmacology in precision medicine	Pharmacol Res Perspect. 2023 Dec;11(6):e01147. doi: 10.1002/prp2.1147.	10.1002/prp2.1147	https://doi.org/10.1002/prp2.1147
Rettie	37784241	2023	Raj PS	Peanut Glycerides	Int J Toxicol. 2023 Dec;42(3_suppl):79S-80S. doi: 10.1177/10915818231204277. Epub 2023 Oct 2.	10.1177/10915818231204277	https://doi.org/10.1177/10915818231204277
Rettie	37776172	2023	Cherian P	Hexamidine and Hexamidine Diisethionate	Int J Toxicol. 2023 Dec;42(3_suppl):51S-52S. doi: 10.1177/10915818231204273. Epub 2023 Sep 30.	10.1177/10915818231204273	https://doi.org/10.1177/10915818231204273
Rettie	37773619	2023	Cherian P	Amyl Acetate and Isoamyl Acetate	Int J Toxicol. 2023 Dec;42(3_suppl):14S-16S. doi: 10.1177/10915818231204262. Epub 2023 Sep 29.	10.1177/10915818231204262	https://doi.org/10.1177/10915818231204262
Rettie	37773611	2023	Burnett CL	Prunus Amygdalus Dulcis (Sweet Almond) Seed Meal	Int J Toxicol. 2023 Dec;42(3_suppl):93S-95S. doi: 10.1177/10915818231204244. Epub 2023 Sep 29.	10.1177/10915818231204244	https://doi.org/10.1177/10915818231204244
Rettie	37769700	2023	Cherian P	Chloroxylenol	Int J Toxicol. 2023 Dec;42(3_suppl):22S-23S. doi: 10.1177/10915818231204263. Epub 2023 Sep 28.	10.1177/10915818231204263	https://doi.org/10.1177/10915818231204263
Rettie	37769693	2023	Tucker R	Glycol Stearate and Glycol Stearate SE	Int J Toxicol. 2023 Dec;42(3_suppl):45S-46S. doi: 10.1177/10915818231204266. Epub 2023 Sep 28.	10.1177/10915818231204266	https://doi.org/10.1177/10915818231204266
Rettie	37769692	2023	Raj PS	Cottonseed Glyceride and Hydrogenated Cottonseed Glyceride	Int J Toxicol. 2023 Dec;42(3_suppl):27S-28S. doi: 10.1177/10915818231204275. Epub 2023 Sep 28.	10.1177/10915818231204275	https://doi.org/10.1177/10915818231204275
Rettie	37767974	2023	Burnett CL	Sodium Lauryl Sulfoacetate	Int J Toxicol. 2023 Dec;42(3_suppl):100S-101S. doi: 10.1177/10915818231204274. Epub 2023 Sep 28.	10.1177/10915818231204274	https://doi.org/10.1177/10915818231204274
Rettie	37767952	2023	Cherian P	PPG-11 and PPG-15 Stearyl Ether	Int J Toxicol. 2023 Dec;42(3_suppl):81S-82S. doi: 10.1177/10915818231204265. Epub 2023 Sep 28.	10.1177/10915818231204265	https://doi.org/10.1177/10915818231204265
Rettie	37767701	2023	Raj PS	Erythorbic Acid and Sodium Erythorbate	Int J Toxicol. 2023 Dec;42(3_suppl):37S-39S. doi: 10.1177/10915818231204257. Epub 2023 Sep 28.	10.1177/10915818231204257	https://doi.org/10.1177/10915818231204257
Rettie	37766629	2023	Raj PS	Polyacrylamide	Int J Toxicol. 2023 Dec;42(3_suppl):89S-90S. doi: 10.1177/10915818231204573. Epub 2023 Sep 28.	10.1177/10915818231204573	https://doi.org/10.1177/10915818231204573
Rettie	37766591	2023	Burnett CL	HC Yellow 5	Int J Toxicol. 2023 Dec;42(3_suppl):49S-50S. doi: 10.1177/10915818231204272. Epub 2023 Sep 27.	10.1177/10915818231204272	https://doi.org/10.1177/10915818231204272
Rettie	37755708	2023	Cherian P	Choleth-24	Int J Toxicol. 2023 Dec;42(3_suppl):24S-26S. doi: 10.1177/10915818231204278. Epub 2023 Sep 27.	10.1177/10915818231204278	https://doi.org/10.1177/10915818231204278
Rettie	37753962	2023	Raj PS	Polyamino Sugar Condensate	Int J Toxicol. 2023 Dec;42(3_suppl):91S-92S. doi: 10.1177/10915818231204239. Epub 2023 Sep 27.	10.1177/10915818231204239	https://doi.org/10.1177/10915818231204239
Rettie	37752772	2023	Raj PS	Methyl Alcohol	Int J Toxicol. 2023 Dec;42(3_suppl):74S-76S. doi: 10.1177/10915818231204251. Epub 2023 Sep 26.	10.1177/10915818231204251	https://doi.org/10.1177/10915818231204251
Rettie	37751626	2023	Burnett CL	Acid Orange 3	Int J Toxicol. 2023 Dec;42(3_suppl):10S-11S. doi: 10.1177/10915818231204252. Epub 2023 Sep 26.	10.1177/10915818231204252	https://doi.org/10.1177/10915818231204252
Rettie	37751605	2023	Tucker R	Phytantriol	Int J Toxicol. 2023 Dec;42(3_suppl):86S-88S. doi: 10.1177/10915818231204241. Epub 2023 Sep 26.	10.1177/10915818231204241	https://doi.org/10.1177/10915818231204241
Rettie	37751584	2023	Cherian P	PEG Soy Sterols	Int J Toxicol. 2023 Dec;42(3_suppl):83S-85S. doi: 10.1177/10915818231204279. Epub 2023 Sep 26.	10.1177/10915818231204279	https://doi.org/10.1177/10915818231204279
Rettie	37751575	2023	Raj PS	Dioscorea Villosa (Wild Yam) Root Extract	Int J Toxicol. 2023 Dec;42(3_suppl):29S-31S. doi: 10.1177/10915818231204230. Epub 2023 Sep 26.	10.1177/10915818231204230	https://doi.org/10.1177/10915818231204230
Rettie	37751399	2023	Raj PS	Glyceryl Diesters	Int J Toxicol. 2023 Dec;42(3_suppl):40S-44S. doi: 10.1177/10915818231204269. Epub 2023 Sep 26.	10.1177/10915818231204269	https://doi.org/10.1177/10915818231204269
Rettie	37751389	2023	Tucker R	Mink Oil	Int J Toxicol. 2023 Dec;42(3_suppl):77S-78S. doi: 10.1177/10915818231204255. Epub 2023 Sep 26.	10.1177/10915818231204255	https://doi.org/10.1177/10915818231204255
Rettie	37541764	2023	Nguyen JT	An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations	J Pharmacol Exp Ther. 2023 Dec;387(3):252-264. doi: 10.1124/jpet.123.001681. Epub 2023 Aug 4.	10.1124/jpet.123.001681	https://doi.org/10.1124/jpet.123.001681
Rettie	37286363	2023	Tanna RS	Translating Kratom-Drug Interactions: From Bedside to Bench and Back	Drug Metab Dispos. 2023 Aug;51(8):923-935. doi: 10.1124/dmd.122.001005. Epub 2023 Jun 7.	10.1124/dmd.122.001005	https://doi.org/10.1124/dmd.122.001005
Totah	38478383	2024	Wiley AM	Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review	Drug Metab Rev. 2024 Feb-May;56(2):145-163. doi: 10.1080/03602532.2024.2329928. Epub 2024 Mar 20.	10.1080/03602532.2024.2329928	https://doi.org/10.1080/03602532.2024.2329928
Totah	37236759	2023	Cho C	Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ÃÂÃÂ-3 and ÃÂÃÂ-6 PUFAs	Adv Pharmacol. 2023;97:201-227. doi: 10.1016/bs.apha.2023.02.001. Epub 2023 Mar 27.	10.1016/bs.apha.2023.02.001	https://doi.org/10.1016/bs.apha.2023.02.001
Totah	40840013	2025	He L	Liver CYP4A autophagic lysosomal degradation: A major role for the autophagic receptor SQSTM1/p62 through an uncommon target interaction site	Mol Pharmacol. 2025 Sep;107(9):100061. doi: 10.1016/j.molpha.2025.100061. Epub 2025 Jul 11.	10.1016/j.molpha.2025.100061	https://doi.org/10.1016/j.molpha.2025.100061
Totah	41002968	2025	Wiley AM	Selective Knockdown of Ceramide Synthases Reveals Opposite Roles of Different Ceramide Species in Cardiac Homeostasis	Metabolites. 2025 Aug 31;15(9):584. doi: 10.3390/metabo15090584.	10.3390/metabo15090584	https://doi.org/10.3390/metabo15090584
Totah	41003018	2025	Wiley AM	Deciphering the Role of Different Ceramide Synthases in the Human Cardiomyocyte Hypertrophic Response	Metabolites. 2025 Sep 22;15(9):635. doi: 10.3390/metabo15090635.	10.3390/metabo15090635	https://doi.org/10.3390/metabo15090635
Totah	32210298	2020	Evangelista EA	CYP2J2 Modulates Diverse Transcriptional Programs in Adult Human Cardiomyocytes	Sci Rep. 2020 Mar 24;10(1):5329. doi: 10.1038/s41598-020-62174-w.	10.1038/s41598-020-62174-w	https://doi.org/10.1038/s41598-020-62174-w
Totah	32486275	2020	Aliwarga T	Higher Epoxyeicosatrienoic Acids in Cardiomyocytes-Specific CYP2J2 Transgenic Mice Are Associated with Improved Myocardial Remodeling	Biomedicines. 2020 May 30;8(6):144. doi: 10.3390/biomedicines8060144.	10.3390/biomedicines8060144	https://doi.org/10.3390/biomedicines8060144
Totah	34921097	2022	Kramlinger VM	Future of Biotransformation Science in the Pharmaceutical Industry	Drug Metab Dispos. 2022 Mar;50(3):258-267. doi: 10.1124/dmd.121.000658. Epub 2021 Dec 17.	10.1124/dmd.121.000658	https://doi.org/10.1124/dmd.121.000658
Totah	35930887	2022	Lemaitre RN	Plasma epoxyeicosatrienoic acids and diabetes-related cardiovascular disease: The cardiovascular health study	EBioMedicine. 2022 Sep;83:104189. doi: 10.1016/j.ebiom.2022.104189. Epub 2022 Aug 2.	10.1016/j.ebiom.2022.104189	https://doi.org/10.1016/j.ebiom.2022.104189
Totah	36293289	2022	Aliwarga T	Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation	Int J Mol Sci. 2022 Oct 17;23(20):12433. doi: 10.3390/ijms232012433.	10.3390/ijms232012433	https://doi.org/10.3390/ijms232012433
Totah	37137720	2023	Russell DA	METTL7A (TMT1A) and METTL7B (TMT1B) Are Responsible for Alkyl S-Thiol Methyl Transferase Activity in Liver	Drug Metab Dispos. 2023 Aug;51(8):1024-1034. doi: 10.1124/dmd.123.001268. Epub 2023 May 3.	10.1124/dmd.123.001268	https://doi.org/10.1124/dmd.123.001268
Totah	37550070	2023	Czuba LC	CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive Metabolizers	Drug Metab Dispos. 2023 Nov;51(11):1474-1482. doi: 10.1124/dmd.123.001358. Epub 2023 Aug 7.	10.1124/dmd.123.001358	https://doi.org/10.1124/dmd.123.001358
Totah	33752126	2021	Lemaitre RN	Plasma epoxyeicosatrienoic acids and dihydroxyeicosatrieonic acids, insulin, glucose and risk of diabetes: The strong heart study	EBioMedicine. 2021 Apr;66:103279. doi: 10.1016/j.ebiom.2021.103279. Epub 2021 Mar 19.	10.1016/j.ebiom.2021.103279	https://doi.org/10.1016/j.ebiom.2021.103279
Totah	33069736	2021	Somani ST	Changes in erythrocyte membrane epoxyeicosatrienoic, dihydroxyeicosatrienoic, and hydroxyeicosatetraenoic acids during pregnancy	Life Sci. 2021 Jan 1;264:118590. doi: 10.1016/j.lfs.2020.118590. Epub 2020 Oct 15.	10.1016/j.lfs.2020.118590	https://doi.org/10.1016/j.lfs.2020.118590
Totah	39728496	2024	Russell DA	A Rapid and Reliable Absorbance Assay to Identify Drug-Drug Interactions with Thiopurine Drugs	Metabolites. 2024 Dec 19;14(12):715. doi: 10.3390/metabo14120715.	10.3390/metabo14120715	https://doi.org/10.3390/metabo14120715
Totah	41453524	2025	Jung T	Hydrogen sulfide attenuates PMA-Induced hypertrophy in human cardiomyocytes by modulating gene expression and reducing sulfide methylation	Biochem Pharmacol. 2025 Dec 24;245:117666. doi: 10.1016/j.bcp.2025.117666. Online ahead of print.	10.1016/j.bcp.2025.117666	https://doi.org/10.1016/j.bcp.2025.117666
Totah	32581794	2020	Evangelista EA	Expression and Function of Eicosanoid-Producing Cytochrome P450 Enzymes in Solid Tumors	Front Pharmacol. 2020 Jun 9;11:828. doi: 10.3389/fphar.2020.00828. eCollection 2020.	10.3389/fphar.2020.00828	https://doi.org/10.3389/fphar.2020.00828
Totah	36174836	2022	Shi Y	Selective deuteration of bupropion slows epimerization and reduces metabolism	Bioorg Med Chem Lett. 2022 Nov 15;76:129009. doi: 10.1016/j.bmcl.2022.129009. Epub 2022 Sep 27.	10.1016/j.bmcl.2022.129009	https://doi.org/10.1016/j.bmcl.2022.129009
Totah	39697552	2024	Adebesin AM	Editorial: Cytochromes P450, their modulators and metabolites in cardiovascular function and disease	Front Pharmacol. 2024 Dec 3;15:1531166. doi: 10.3389/fphar.2024.1531166. eCollection 2024.	10.3389/fphar.2024.1531166	https://doi.org/10.3389/fphar.2024.1531166
Totah	35163358	2022	Cho C	Reductions in Hydrogen Sulfide and Changes in Mitochondrial Quality Control Proteins Are Evident in the Early Phases of the Corneally Kindled Mouse Model of Epilepsy	Int J Mol Sci. 2022 Jan 27;23(3):1434. doi: 10.3390/ijms23031434.	10.3390/ijms23031434	https://doi.org/10.3390/ijms23031434
Totah	36837861	2023	Enthoven LF	The Effects of Pregnancy on Amino Acid Levels and Nitrogen Disposition	Metabolites. 2023 Feb 7;13(2):242. doi: 10.3390/metabo13020242.	10.3390/metabo13020242	https://doi.org/10.3390/metabo13020242
Totah	37001802	2023	Zeigler MB	Plasma hydrogen sulfide, nitric oxide, and thiocyanate levels are lower during pregnancy compared to postpartum in a cohort of women from the Pacific northwest of the United States	Life Sci. 2023 Jun 1;322:121625. doi: 10.1016/j.lfs.2023.121625. Epub 2023 Mar 30.	10.1016/j.lfs.2023.121625	https://doi.org/10.1016/j.lfs.2023.121625
Totah	37755306	2023	Enthoven LF	Effects of Pregnancy on Plasma Sphingolipids Using a Metabolomic and Quantitative Analysis Approach	Metabolites. 2023 Sep 21;13(9):1026. doi: 10.3390/metabo13091026.	10.3390/metabo13091026	https://doi.org/10.3390/metabo13091026
Totah	32955894	2020	Basit A	Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human	Mol Pharm. 2020 Nov 2;17(11):4114-4124. doi: 10.1021/acs.molpharmaceut.0c00559. Epub 2020 Oct 2.	10.1021/acs.molpharmaceut.0c00559	https://doi.org/10.1021/acs.molpharmaceut.0c00559
Totah	38494918	2024	Bercu JP	A Case to Support the Continued Use of Rifampin in Clinical Drug-Drug Interaction Studies	Clin Pharmacol Ther. 2024 Jul;116(1):34-37. doi: 10.1002/cpt.3256. Epub 2024 Mar 18.	10.1002/cpt.3256	https://doi.org/10.1002/cpt.3256
Totah	33649426	2021	Maldonato BJ	Human METTL7B is an alkyl thiol methyltransferase that metabolizes hydrogen sulfide and captopril	Sci Rep. 2021 Mar 1;11(1):4857. doi: 10.1038/s41598-021-84218-5.	10.1038/s41598-021-84218-5	https://doi.org/10.1038/s41598-021-84218-5
Totah	34272705	2021	Lin YS	Sources of Interindividual Variability	Methods Mol Biol. 2021;2342:481-550. doi: 10.1007/978-1-0716-1554-6_17.	10.1007/978-1-0716-1554-6_17	https://doi.org/10.1007/978-1-0716-1554-6_17
Totah	38151817	2024	Robey RW	The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors	Mol Cancer Ther. 2024 Apr 2;23(4):464-477. doi: 10.1158/1535-7163.MCT-23-0144.	10.1158/1535-7163.MCT-23-0144	https://doi.org/10.1158/1535-7163.mct-23-0144
Totah	39464120	2024	He L	Liver CYP4A autophagic-lysosomal degradation (ALD): A major role for the autophagic receptor SQSTM1/p62 through an uncommon target interaction site	bioRxiv [Preprint]. 2024 Oct 14:2024.10.14.618315. doi: 10.1101/2024.10.14.618315.	10.1101/2024.10.14.618315	https://doi.org/10.1101/2024.10.14.618315
Xu	41735104	2026	Xu L	Corrigendum to "Effusol ameliorates ischemic stroke by targeting NLRP3 protein to regulate NLRP3 inflammasome-mediated pyroptosis"	Xu L, Li S, Qi J, Mi Y, Zhang Y, Yang Y, Wang Y, Zhou D, Li N, Hou Y. Corrigendum to "Effusol ameliorates ischemic stroke by targeting NLRP3 protein to regulate NLRP3 inflammasome-mediated pyroptosis" [Phytomedicine, 136 (2025) 156253/PMID: 39615210]. Phytomedicine. 2026 Mar;152:157834. doi: 10.1016/j.phymed.2026.157834. Epub 2026 Feb 3. Erratum for: Phytomedicine. 2025 Jan;136:156253. doi: 10.1016/j.phymed.2024.156253.	10.1016/j.phymed.2026.157834	https://doi.org/10.1016/j.phymed.2026.157834	4/28/26
Xu	41880181	2026	Adcock L	Differential and Sex-Specific Toxicity of Aspirated Quaternary Ammonium Compounds	Adcock L, Montgomery CB, Barkhordari S, Datta S, Van Winkle L, Seguin R, Xu L, Kim K, Cortopassi G. Differential and Sex-Specific Toxicity of Aspirated Quaternary Ammonium Compounds. Environ Sci Technol. 2026 Apr 7;60(13):9872-9880. doi: 10.1021/acs.est.5c13204. Epub 2026 Mar 25. PMID: 41880181; PMCID: PMC13063409.	10.1021/acs.est.5c13204	https://doi.org/10.1021/acs.est.5c13204	4/28/26
Xu	41822371	2026	Stohs EJ	Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil	Stohs EJ, Alexander BT, Fey PD, Foreman MCL, Xu L, Penewit K, Waalkes A, Salipante SJ, Werth BJ. Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil. Open Forum Infect Dis. 2026 Feb 16;13(3):ofag074. doi: 10.1093/ofid/ofag074. PMID: 41822371; PMCID: PMC12978522.	10.1093/ofid/ofag074	https://doi.org/10.1093/ofid/ofag074	4/28/26
Xu	41820720	2026	Cheng R,	Assessing the Recovery of Muscle Fatigue Using Shear Wave Elastography	Cheng R, Wang Q, Xu L, Xu W, Zheng Y, Cui Y, Cao Y. Assessing the Recovery of Muscle Fatigue Using Shear Wave Elastography. Sports Med Open. 2026 Mar 12;12(1):30. doi: 10.1186/s40798-026-00991-5.	10.1186/s40798-026-00991-5	https://doi.org/10.1186/s40798-026-00991-5	4/28/26
Xu	41793791	2026	Xu L	KLK8 promotes cartilage degradation and pyroptosis in osteoarthritis by activating the NF-ÃÂÃÂºB and NLRP3 inflammasome pathways	Xu L, Jiang Z, Li H. KLK8 promotes cartilage degradation and pyroptosis in osteoarthritis by activating the NF-ÃÂÃÂºB and NLRP3 inflammasome pathways. Tissue Cell. 2026 Feb 27;101:103427. doi: 10.1016/j.tice.2026.103427. Epub ahead of print.	10.1016/j.tice.2026.103427	https://doi.org/10.1016/j.tice.2026.103427	4/28/26
Xu	40140573	2025	Ha YJ	The contribution of de novo coding mutations to meningomyelocele	Nature. 2025 May;641(8062):419-426. doi: 10.1038/s41586-025-08676-x. Epub 2025 Mar 26.	10.1038/s41586-025-08676-x	https://doi.org/10.1038/s41586-025-08676-x
Xu	37157132	2023	Arnold WA	Quaternary Ammonium Compounds: A Chemical Class of Emerging Concern	Environ Sci Technol. 2023 May 23;57(20):7645-7665. doi: 10.1021/acs.est.2c08244. Epub 2023 May 8.	10.1021/acs.est.2c08244	https://doi.org/10.1021/acs.est.2c08244
Xu	39405116	2024	Nguyen AH	Molecular basis of cell membrane adaptation in daptomycin-resistant Enterococcus faecalis	JCI Insight. 2024 Nov 22;9(22):e173836. doi: 10.1172/jci.insight.173836.	10.1172/jci.insight.173836	https://doi.org/10.1172/jci.insight.173836
Xu	33736803	2021	Ross DH	Determination of drugs and drug metabolites by ion mobility-mass spectrometry: A review	Anal Chim Acta. 2021 Apr 15;1154:338270. doi: 10.1016/j.aca.2021.338270. Epub 2021 Feb 2.	10.1016/j.aca.2021.338270	https://doi.org/10.1016/j.aca.2021.338270
Xu	36111785	2022	Tomita H	7-Dehydrocholesterol-derived oxysterols cause neurogenic defects in Smith-Lemli-Opitz syndrome	Elife. 2022 Sep 16;11:e67141. doi: 10.7554/eLife.67141.	10.7554/eLife.67141	https://doi.org/10.7554/elife.67141
Nath	39837577	2025	Tuttle LM	Rigorous Analysis of Multimodal HDX-MS Spectra	J Am Soc Mass Spectrom. 2025 Feb 5;36(2):416-423. doi: 10.1021/jasms.4c00471. Epub 2025 Jan 21.	10.1021/jasms.4c00471	https://doi.org/10.1021/jasms.4c00471	4/28/26
Xu	40133959	2025	Li J	Radiation-induced ferroptosis via liposomal delivery of 7-Dehydrocholesterol	J Nanobiotechnology. 2025 Mar 26;23(1):249. doi: 10.1186/s12951-025-03303-3.	10.1186/s12951-025-03303-3	https://doi.org/10.1186/s12951-025-03303-3
Nath	41899522	2026	Mariano IP	Biophysical and Structural Characterization of Antibody-Drug Conjugates	Mariano IP, Nath A. Biophysical and Structural Characterization of Antibody-Drug Conjugates. Cancers (Basel). 2026 Mar 12;18(6):917. doi: 10.3390/cancers18060917. PMID: 41899522; PMCID: PMC13024996.	10.3390/cancers18060917	https://doi.org/10.3390/cancers18060917
Xu	38077958	2023	Elias ER	Cholic acid increases plasma cholesterol in Smith-Lemli-Opitz syndrome: A pilot study	Mol Genet Metab Rep. 2023 Nov 28;38:101030. doi: 10.1016/j.ymgmr.2023.101030. eCollection 2024 Mar.	10.1016/j.ymgmr.2023.101030	https://doi.org/10.1016/j.ymgmr.2023.101030
Nath	38478383	2024	Wiley AM	Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review	Drug Metab Rev. 2024 Feb-May;56(2):145-163. doi: 10.1080/03602532.2024.2329928. Epub 2024 Mar 20.	10.1080/03602532.2024.2329928	https://doi.org/10.1080/03602532.2024.2329928
Xu	33284321	2021	Findakly S	Sterol and oxysterol synthases near the ciliary base activate the Hedgehog pathway	J Cell Biol. 2021 Jan 4;220(1):e202002026. doi: 10.1083/jcb.202002026.	10.1083/jcb.202002026	https://doi.org/10.1083/jcb.202002026
Nath	35147406	2022	Baggett DW	Structure-Activity Relationships of Novel Tau Ligands: Passive Fibril Binders and Active Aggregation Inhibitors	ACS Chem Biol. 2022 Mar 18;17(3):701-708. doi: 10.1021/acschembio.2c00012. Epub 2022 Feb 11.	10.1021/acschembio.2c00012	https://doi.org/10.1021/acschembio.2c00012
Xu	35548857	2022	Ross DH	High-Throughput Measurement and Machine Learning-Based Prediction of Collision Cross Sections for Drugs and Drug Metabolites	J Am Soc Mass Spectrom. 2022 Jun 1;33(6):1061-1072. doi: 10.1021/jasms.2c00111. Epub 2022 May 11.	10.1021/jasms.2c00111	https://doi.org/10.1021/jasms.2c00111
Xu	38322411	2023	Do Q	How do different lipid peroxidation mechanisms contribute to ferroptosis?	Cell Rep Phys Sci. 2023 Dec 20;4(12):101683. doi: 10.1016/j.xcrp.2023.101683. Epub 2023 Nov 17.	10.1016/j.xcrp.2023.101683	https://doi.org/10.1016/j.xcrp.2023.101683
Xu	39276938	2024	Hass DT	Acetyl-CoA carboxylase inhibition increases retinal pigment epithelial cell fatty acid flux and restricts apolipoprotein efflux	J Biol Chem. 2024 Oct;300(10):107772. doi: 10.1016/j.jbc.2024.107772. Epub 2024 Sep 12.	10.1016/j.jbc.2024.107772	https://doi.org/10.1016/j.jbc.2024.107772
Xu	38307853	2024	Vieira LS	Interaction and Transport of Benzalkonium Chlorides by the Organic Cation and Multidrug and Toxin Extrusion Transporters	Drug Metab Dispos. 2024 Mar 13;52(4):312-321. doi: 10.1124/dmd.123.001625.	10.1124/dmd.123.001625	https://doi.org/10.1124/dmd.123.001625
Xu	37124288	2023	Do Q	Differential Contributions of Distinct Free Radical Peroxidation Mechanisms to the Induction of Ferroptosis	JACS Au. 2023 Mar 4;3(4):1100-1117. doi: 10.1021/jacsau.2c00681. eCollection 2023 Apr 24.	10.1021/jacsau.2c00681	https://doi.org/10.1021/jacsau.2c00681
Xu	37425828	2023	Pruitt EL	Elucidating the Impact of Bacterial Lipases, Human Serum Albumin, and FASII Inhibition on the Utilization of Exogenous Fatty Acids by Staphylococcus aureus	bioRxiv [Preprint]. 2023 Jun 30:2023.06.29.547085. doi: 10.1101/2023.06.29.547085.	10.1101/2023.06.29.547085	https://doi.org/10.1101/2023.06.29.547085
Xu	35504891	2022	Lo M	CNPY4 inhibits the Hedgehog pathway by modulating membrane sterol lipids	Nat Commun. 2022 May 3;13(1):2407. doi: 10.1038/s41467-022-30186-x.	10.1038/s41467-022-30186-x	https://doi.org/10.1038/s41467-022-30186-x
Xu	38534032	2024	Nguyen R	Development and Application of a Multidimensional Database for the Detection of Quaternary Ammonium Compounds and Their Phase I Hepatic Metabolites in Humans	Environ Sci Technol. 2024 Apr 9;58(14):6236-6249. doi: 10.1021/acs.est.3c10845. Epub 2024 Mar 27.	10.1021/acs.est.3c10845	https://doi.org/10.1021/acs.est.3c10845
Xu	37523294	2023	Reimers N	Tracking the Metabolic Fate of Exogenous Arachidonic Acid in Ferroptosis Using Dual-Isotope Labeling Lipidomics	J Am Soc Mass Spectrom. 2023 Sep 6;34(9):2016-2024. doi: 10.1021/jasms.3c00181. Epub 2023 Jul 31.	10.1021/jasms.3c00181	https://doi.org/10.1021/jasms.3c00181
Xu	37535099	2023	Zhang R	High-throughput analysis of lipidomic phenotypes of methicillin-resistant Staphylococcus aureus by coupling in situ 96-well cultivation and HILIC-ion mobility-mass spectrometry	Anal Bioanal Chem. 2023 Oct;415(25):6191-6199. doi: 10.1007/s00216-023-04890-6. Epub 2023 Aug 3.	10.1007/s00216-023-04890-6	https://doi.org/10.1007/s00216-023-04890-6
Xu	35293916	2022	Li A	Temporal changes in the brain lipidome during neurodevelopment of Smith-Lemli-Opitz syndrome mice	Analyst. 2022 Apr 11;147(8):1611-1621. doi: 10.1039/d2an00137c.	10.1039/d2an00137c	https://doi.org/10.1039/d2an00137c
Xu	39363503	2024	Lopez VA	Oral exposure to benzalkonium chlorides in male and female mice reveals alteration of the gut microbiome and bile acid profile	Toxicol Sci. 2024 Dec 1;202(2):265-277. doi: 10.1093/toxsci/kfae116.	10.1093/toxsci/kfae116	https://doi.org/10.1093/toxsci/kfae116
Xu	41388019	2025	Chac D	Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigens	Nat Commun. 2025 Dec 12. doi: 10.1038/s41467-025-67388-y. Online ahead of print.	10.1038/s41467-025-67388-y	https://doi.org/10.1038/s41467-025-67388-y
Xu	38014966	2023	Pruitt EL	Elucidating the impact of bacterial lipases, human serum albumin, and FASII inhibition on the utilization of exogenous fatty acids by Staphylococcus aureus	mSphere. 2023 Dec 20;8(6):e0036823. doi: 10.1128/msphere.00368-23. Epub 2023 Nov 28.	10.1128/msphere.00368-23	https://doi.org/10.1128/msphere.00368-23
Xu	41366203	2025	Zhao HN	A resource to empirically establish drug exposure records directly from untargeted metabolomics data	Nat Commun. 2025 Dec 9;16(1):10600. doi: 10.1038/s41467-025-65993-5.	10.1038/s41467-025-65993-5	https://doi.org/10.1038/s41467-025-65993-5
Xu	39416075	2024	Zhao HN	Empirically establishing drug exposure records directly from untargeted metabolomics data	bioRxiv [Preprint]. 2024 Oct 26:2024.10.07.617109. doi: 10.1101/2024.10.07.617109.	10.1101/2024.10.07.617109	https://doi.org/10.1101/2024.10.07.617109
Xu	35175195	2022	Ting SY	Discovery of coordinately regulated pathways that provide innate protection against interbacterial antagonism	Elife. 2022 Feb 17;11:e74658. doi: 10.7554/eLife.74658.	10.7554/eLife.74658	https://doi.org/10.7554/elife.74658
Xu	39192580	2024	Weakly HMJ	Several common methods of making vesicles (except an emulsion method) capture intended lipid ratios	Biophys J. 2024 Oct 1;123(19):3452-3462. doi: 10.1016/j.bpj.2024.08.019. Epub 2024 Aug 26.	10.1016/j.bpj.2024.08.019	https://doi.org/10.1016/j.bpj.2024.08.019
Xu	33652836	2021	Pfeffer BA	Transcriptomic Changes Associated with Loss of Cell Viability Induced by Oxysterol Treatment of a Retinal Photoreceptor-Derived Cell Line: An In Vitro Model of Smith-Lemli-Opitz Syndrome	Int J Mol Sci. 2021 Feb 26;22(5):2339. doi: 10.3390/ijms22052339.	10.3390/ijms22052339	https://doi.org/10.3390/ijms22052339
Xu	38746422	2024	Raskovic D	Growth of Staphylococcus aureus in the presence of oleic acid shifts the glycolipid fatty acid profile and increases resistance to antimicrobial peptides	bioRxiv [Preprint]. 2024 May 5:2024.05.03.592415. doi: 10.1101/2024.05.03.592415.	10.1101/2024.05.03.592415	https://doi.org/10.1101/2024.05.03.592415
Xu	37577529	2023	Daggubati V	Hedgehog target genes regulate lipid metabolism to drive basal cell carcinoma and medulloblastoma	Res Sq [Preprint]. 2023 Aug 3:rs.3.rs-3058335. doi: 10.21203/rs.3.rs-3058335/v1.	10.21203/rs.3.rs-3058335/v1	https://doi.org/10.21203/rs.3.rs-3058335/v1
Xu	33868951	2021	Hrubec TC	Altered toxicological endpoints in humans from common quaternary ammonium compound disinfectant exposure	Toxicol Rep. 2021 Mar 9;8:646-656. doi: 10.1016/j.toxrep.2021.03.006. eCollection 2021.	10.1016/j.toxrep.2021.03.006	https://doi.org/10.1016/j.toxrep.2021.03.006
Xu	33476305	2021	Daggubati V	Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models	J Clin Invest. 2021 Mar 15;131(6):e141171. doi: 10.1172/JCI141171.	10.1172/JCI141171	https://doi.org/10.1172/jci141171
Xu	33057715	2021	Shen T	Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage	J Antimicrob Chemother. 2021 Jan 19;76(2):292-296. doi: 10.1093/jac/dkaa422.	10.1093/jac/dkaa422	https://doi.org/10.1093/jac/dkaa422
Xu	34646861	2021	Zhang R	Synergy Between Beta-Lactams and Lipo-, Glyco-, and Lipoglycopeptides, Is Independent of the Seesaw Effect in Methicillin-Resistant Staphylococcus aureus	Front Mol Biosci. 2021 Sep 9;8:688357. doi: 10.3389/fmolb.2021.688357. eCollection 2021.	10.3389/fmolb.2021.688357	https://doi.org/10.3389/fmolb.2021.688357
Xu	33269585	2021	Do Q	Development and Application of a Peroxyl Radical Clock Approach for Measuring Both Hydrogen-Atom Transfer and Peroxyl Radical Addition Rate Constants	J Org Chem. 2021 Jan 1;86(1):153-168. doi: 10.1021/acs.joc.0c01920. Epub 2020 Dec 3.	10.1021/acs.joc.0c01920	https://doi.org/10.1021/acs.joc.0c01920
Xu	37873113	2025	Li A	MALDI-IM-MS Imaging of Brain Sterols and Lipids in a Mouse Model of Smith-Lemli-Opitz Syndrome	bioRxiv [Preprint]. 2025 Aug 12:2023.10.02.560415. doi: 10.1101/2023.10.02.560415.	10.1101/2023.10.02.560415	https://doi.org/10.1101/2023.10.02.560415
Xu	37904970	2023	Miller WR	Membrane Lipids Augment Cell Envelope Stress Signaling and Resistance to Antibiotics and Antimicrobial Peptides in Enterococcus faecalis	bioRxiv [Preprint]. 2023 Oct 19:2023.10.17.562839. doi: 10.1101/2023.10.17.562839.	10.1101/2023.10.17.562839	https://doi.org/10.1101/2023.10.17.562839
Xu	32866650	2021	Werth BJ	Dalbavancin exposure inÃÂÃÂ vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus	Clin Microbiol Infect. 2021 Jun;27(6):910.e1-910.e8. doi: 10.1016/j.cmi.2020.08.025. Epub 2020 Aug 28.	10.1016/j.cmi.2020.08.025	https://doi.org/10.1016/j.cmi.2020.08.025
Xu	34179085	2021	Shen T	Varied Contribution of Phospholipid Shedding From Membrane to Daptomycin Tolerance in Staphylococcus aureus	Front Mol Biosci. 2021 Jun 11;8:679949. doi: 10.3389/fmolb.2021.679949. eCollection 2021.	10.3389/fmolb.2021.679949	https://doi.org/10.3389/fmolb.2021.679949
Xu	35510938	2022	Zhang R	Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization	Clin Infect Dis. 2022 Oct 29;75(9):1641-1644. doi: 10.1093/cid/ciac341.	10.1093/cid/ciac341	https://doi.org/10.1093/cid/ciac341
Xu	39936452	2025	Werth BJ	Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials	J Antimicrob Chemother. 2025 Apr 2;80(4):1108-1115. doi: 10.1093/jac/dkaf042.	10.1093/jac/dkaf042	https://doi.org/10.1093/jac/dkaf042
Xu	33472002	2021	Herron JM	Benzalkonium Chloride Disinfectants Induce Apoptosis, Inhibit Proliferation, and Activate the Integrated Stress Response in a 3-D in Vitro Model of Neurodevelopment	Chem Res Toxicol. 2021 May 17;34(5):1265-1274. doi: 10.1021/acs.chemrestox.0c00386. Epub 2021 Jan 20.	10.1021/acs.chemrestox.0c00386	https://doi.org/10.1021/acs.chemrestox.0c00386
Xu	39500386	2025	Raskovic D	Growth of Staphylococcus aureus in the presence of oleic acid shifts the glycolipid fatty acid profile and increases resistance to antimicrobial peptides	Biochim Biophys Acta Biomembr. 2025 Jan;1867(1):184395. doi: 10.1016/j.bbamem.2024.184395. Epub 2024 Nov 3.	10.1016/j.bbamem.2024.184395	https://doi.org/10.1016/j.bbamem.2024.184395
Xu	38045361	2025	Li A	Temporal transcriptomic changes during neurodevelopment in a mouse model of Smith-Lemli-Opitz syndrome	bioRxiv [Preprint]. 2025 Aug 12:2023.11.21.568116. doi: 10.1101/2023.11.21.568116.	10.1101/2023.11.21.568116	https://doi.org/10.1101/2023.11.21.568116
Xu	39957787	2025	Elapavalore A	PubChemLite Plus Collision Cross Section (CCS) Values for Enhanced Interpretation of Nontarget Environmental Data	Environ Sci Technol Lett. 2025 Jan 24;12(2):166-174. doi: 10.1021/acs.estlett.4c01003. eCollection 2025 Feb 11.	10.1021/acs.estlett.4c01003	https://doi.org/10.1021/acs.estlett.4c01003
Xu	41190598	2025	Kula J	Maternal and Placental Inflammation Influence Formation of Neural Tube Defects in Quaternary Ammonium Compound Exposed Mice	Birth Defects Res. 2025 Nov;117(11):e2539. doi: 10.1002/bdr2.2539.	10.1002/bdr2.2539	https://doi.org/10.1002/bdr2.2539
Xu	41506459	2026	Li A	Temporal transcriptomic changes during neurodevelopment in a mouse model of Smith-Lemli-Opitz syndrome	Li A, Tomita H, Xu L. Temporal transcriptomic changes during neurodevelopment in a mouse model of Smith-Lemli-Opitz syndrome. J Steroid Biochem Mol Biol. 2026 Mar;257:106935. doi: 10.1016/j.jsbmb.2026.106935. Epub 2026 Jan 6.	10.1016/j.jsbmb.2026.106935	https://doi.org/10.1016/j.jsbmb.2026.106935	4/28/26
Xu	38578967	2025	Miller WR	Membrane Lipids Augment Cell Envelope Stress Signaling via the MadRS System to Defend Against Antimicrobial Peptides and Antibiotics in Enterococcus faecalis	J Infect Dis. 2025 Feb 20;231(2):307-317. doi: 10.1093/infdis/jiae173.	10.1093/infdis/jiae173	https://doi.org/10.1093/infdis/jiae173
Xu	40912167	2025	Colonna MB	Expansion of genotype/phenotype correlation in an individual with compound heterozygous variants in CYP51A1 and congenital cataract	Mol Genet Metab. 2025 Sep-Oct;146(1-2):109230. doi: 10.1016/j.ymgme.2025.109230. Epub 2025 Sep 2.	10.1016/j.ymgme.2025.109230	https://doi.org/10.1016/j.ymgme.2025.109230